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REGULATING RESEARCH ON THE
TERMINALLY ILL: A PROPOSAL FOR
HEIGHTENED SAFEGUARDS
D. Christian Addicott*
Within a year, if all goes well, the first cancer patient will be
injected with two new drugs that can eradicate any type of can-
cer, with no obvious side effects and no drug resistance...
These are heady times for researchers searching for cures, therapies,
or vaccines for terminal illnesses ranging from cancer to AIDS to Alz-
heimer's. Gene therapy and other advances in biotechnology have
opened up new areas of research and spawned a major industry devoted
to the development, and eventual marketing, of new treatments.2 The
potential payoff, in both human and financial terms, is huge. Investors
are betting billions of dollars on start-up biotechnology companies, 3 and
patients desperate for a cure are vigorously competing to be included as
research subjects.
4
Yet lurking beneath this optimism is risk. Investors must contend with
a highly volatile market in which most companies they pick will be los-
ers.5 For those suffering from terminal illnesses, the risk is more pro-
found. They must contend with the likelihood that their dreams of a cure
will prove to be illusory, and with the chance that the experimental
* B.A., Columbia College; J.D., University of Washington; Law Clerk to the
Honorable William L. Dwyer. The author would like to thank Professors Patricia
C. Kuszler and Anna C. Mastroianni for their insightful comments and guidance in
the preparation of this Article. This Article is dedicated to Kathryn Lee Hamilton,
1944-1993.
1. Gina Kolata, A Cautious Awe Greets Drugs That Eradicate Tumors in
Mice, N.Y. TIMES, May 3, 1998, at Al.
2. See Special Report: Curing Cancer - How to Tell the Hype from the
Hope, TIME, May 18, 1998, at 38-51 [hereinafter TIME Special Report].
3. See Andrew Pollack, For Biotechnology Investors, A Week of Lessons on
Volatility, N.Y. TIMES, May 10, 1998, at B6.
4. See Kolata, supra note 1, at A I (stating that even before receiving any
publicity a developer of potential new cancer drugs received "hundreds of calls a
day from cancer patients, pleading for the drugs").
5. See Pollack, supra note 3, at B6.
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treatments they receive may injure or kill them. 6 First-hand experience
with this risk has led me to question the sufficiency of the informed con-
sent paradigm as applied to research involving the terminally ill as sub-
jects.
In 1993, my mother, who was suffering from metastatic breast cancer,
died of "regimen-related toxicities" while participating in research de-
signed to determine the maximum tolerable dose of busulfan and cytoxin
that could be administered safely in conjunction with an autologous pe-
ripheral stem cell transplant.7 Deciding whether to participate in the
study was difficult for her. Despite familiarity with the medical jargon, a
graduate degree in health administration, and twenty years of experience
working in hospitals, she had great difficulty analyzing the risks and
benefits rationally. Because of the fear, anxiety, and sadness she felt
knowing that her death was an imminent possibility, logic seemed to fail
her. Ultimately, her decision was based more on emotion, intuition, and
the advice of her doctors.
6. Both the benefits and risks of human research are often exaggerated. For
example, in Phase I cancer trials, response rates as low as four to six percent are
sometimes seen, and complete responses are extremely rare. However, the chance
of having a fatal reaction to the drugs tested in these studies is between one-half
and one percent. See Christopher K. Daugherty et al., Learning from Our Patients:
One Participant's Impact on Clinical Trial Research and Informed Consent, 126
ANNALS INTERNAL MED. 892, 896 (1997) (citing G. Decoster et al., Responses and
Toxic Deaths in Phase I Clinical Trials, 1 ANNALS ONCOL. 175 (1990); D.D. Van
Hoff & J. Turner, Response Rates, Duration of Response, and Dose Response Ef-
fects in Phase I Studies ofAntineoplastics, 9 INVEST. NEW DRUGS 115 (1991)).
7. Busalfan and cytoxin are common cancer chemotherapy drugs. Stem cells
are produced by bone marrow and mature into the blood cells, such as T-cells, that
comprise the front lines of the immune system. Chemotherapy kills cells that, like
cancer cells, multiply quickly. Because stem cells also multiply quickly, high-dose
chemotherapy cripples the immune system. An autologous stem cell transplant
seeks to avoid this side effect by collecting healthy stem cells from the patient prior
to chemotherapy, and then reintroducing the cells into the body after the chemo-
therapy drugs have been flushed from the patient's system. The term "regimen-
related toxicities" refers to side effects of the research protocol as opposed to ef-
fects of illness.
Research has yet to establish "whether high-dose chemotherapy (HDC) followed
by bone marrow or peripheral blood stem-cell transplant offers breast cancer pa-
tients better survival odds than conventional treatment." Joan Stephenson, Re-
searchers Struggle with Trial of Stem-cell Transplants for Breast Cancer, 277
JAMA 1827, 1827 (1997).
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If someone experienced and educated in the medical field had such
difficulty understanding and weighing the risks, what does it really
mean for terminally ill patients to give their "informed consent" to par-
ticipate in research that has the potential to save or extinguish their
lives? Is the current regulatory system adequate to ensure that the termi-
nally ill are not taken advantage of when they participate in such re-
search? Does it ensure that they receive the information necessary to
make these difficult decisions? And does it prevent inattentive or un-
ethical researchers from coercing the terminally ill into participating in
experiments that may not be in their best interest? These are the central
questions to which this Article responds.
Part I of this Article describes the modern federal regulatory system in
the United States. Part II argues that the terminally ill are vulnerable to
research abuse for a variety of reasons. Part III proposes and analyzes
potential regulatory reforms designed to better protect the unique inter-
ests of terminally ill research subjects. This Article concludes that the
following regulatory reforms should be adopted:
(1) The terminally ill should be classified under the regulations
as a vulnerable population;
(2) Institutional Review Boards (IRBs) that approve research in-
volving the terminally ill should be required to include or con-
sult with at least one member who would represent the interests
of the terminally ill;
(3) Researchers who involve the terminally ill as subjects should
be trained to recognize the psychological difficulties that the
terminally ill face;
(4) With a few exceptions, research on the terminally ill should
be prohibited unless it is intended to provide a therapeutic bene-
fit to the subjects;
(5) Terminally ill patients should receive psychological evalua-
tions before participating in research studies; and
(6) Subject advocates should be available to assist the terminally
ill during the informed consent process.
I. FEDERAL REGULATION OF RESEARCH
INVOLVING HUMAN SUBJECTS
Research with human subjects in the United States is peer-reviewed
by local Institutional Review Boards. The primary obligations of IRBs
are to ensure that research conducted at each institution is ethically and
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scientifically sound - based on a determination that the risks posed to
the research subjects are justified by the potential benefits of the re-
search - and to ensure that the participants in these studies are selected
in an equitable manner and give their informed, voluntary consent prior
to participating. Additional protections are provided for children, pris-
oners, and other "vulnerable" populations, but the terminally ill are not
identified as "vulnerable," and no specific regulations are in place to
protect their interests. Indeed, after heavy lobbying by AIDS activists
and others, some of the regulatory hurdles for approval of and access to
new drugs have been lowered.
A. General Regulatory Framework
The federal regulations8 lay out broad guidelines for the conduct of
research involving human subjects with which IRBs must comply. There
are structural regulations governing the composition and duties of IRBs,
substantive regulations governing the types of research that may be con-
8. Regulations governing "research sponsored by Department of Health and
Human Services (HHS), codified at 45 C.F.R. §§ 46.101-46.124 (1998) served as
the model for the development of the "Federal Policy for the Protection of Human
Subjects." PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN
MEDICINE AND BIOMEDICAL AND BEHAVIORAL RESEARCH, IMPLEMENTING HUMAN
RESEARCH REGULATIONS 1 (1983). These rules, referred to collectively herein as
"the regulations," or "the federal regulations," have been adopted by the various
federal agencies that conduct or sponsor human subject research: the Department of
Agriculture (7 C.F.R pt. 1c), the Deliartment of Energy (10 C.F.R. pt. 745), the
National Aeronautics and Space Administration (14 C.F.R. pt. 1230), the Depart-
ment of Commerce (14 C.F.R. pt. 1230; 15 C.F.R. pt. 27), the Consumer Product
Safety Commission (16 C.F.R. pt. 1028), the International Development Coopera-
tion Agency, Agency for International Development (22 C.F.R. pt. 225), the De-
partment of Housing and Urban Development (24 C.F.R. pt. 60), the Department of
Justice (28 C.F.R. pt. 46), the Department of Defense (32 C.F.R. pt. 219), the De-
partment of Veterans Affairs (38 C.F.R. pt. 16), the Environmental Protection
Agency (40 C.F.R. pt. 26), the National Science Foundation (45 C.F.R pt. 690),
and the Department of Transportation (49 C.F.R. pt. 11). Similar regulations have
been adopted by the Food and Drug Administration (FDA) for the investigation of
new drugs. See 21 C.F.R. pts. 312, 314. Except where noted, all references in this
Article to the federal regulations are to the HHS regulations; however, the argu-
ments made are equally applicable to research sponsored by other federal agencies.
For an excellent summary of these regulations, see JEREMY SUGARMAN ET AL.,
ETHICS OF RESEARCH WITH HUMAN SUBJECTS: SELECTED POLICIES AND
RESOURCES (1998).
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ducted, and procedural rules to ensure that subjects give their informed
consent.
1. Institutional Review Boards
IRBs are the backbone of the federal regulatory system. 9 For the most
part, federal regulatory agencies do not regulate research involving hu-
man subjects directly. Instead, IRBs perform the critical functions of
reviewing, approving, monitoring, and, where appropriate, terminating
research.' 0 Before approving research, an IRB must find that subject risk
will be minimized; that risks are reasonable relative to benefits; that
selection of subjects is equitable; that material facts will be disclosed;.
that the subjects will give their informed, voluntary consent; that there
will be ongoing risk/benefit analysis; that subjects' privacy will be
maintained; and that there are additional safeguards for "vulnerable"
subjects."
Originally, IRBs were comprised almost exclusively of physicians and
scientists who were peers of the researchers whose projects they re-
viewed. 12 In response to concerns that this arrangement involved a con-
flict of interest, the regulations subsequently were revised to require
more diversity. Current regulations mandate that each IRB have at least
five members, "with varying backgrounds to promote complete and ade-
quate review of research activities commonly conducted by the institu-
tion. '13 Racial and ethnic diversity must be taken into account.' 4 If re-
search involving vulnerable populations is regularly reviewed, someone
with knowledge about those populations should be included on the
IRB.'5 There must be at least one person whose "primary area of con-
9. For a comprehensive description and analysis of the evolution and current
role of IRBs, see ROBERT J. LEVINE, ETHICS AND REGULATION OF CLINICAL
RESEARCH 321-63 (2d ed. 1986).
10. See 45 C.F.R. §§ 46.101-46.124; LEVINE, supra note 9, at 321-63.
11. See 45 C.F.R. § 46.111(1998). One leading commentator identifies six
ethical norms that underlie most codes and regulations governing research on hu-
man subjects: "There should be 1) good research design, 2) competent investiga-
tors, 3) a favorable balance of harm and benefit, 4) informed consent ... 5) equita-
ble selection of subjects . . . [and] 6) there should be compensation for research-
related injury." LEVINE, supra note 9, at 19.
12. LEVINE, supra note 9, at 323-25.
13. 45 C.F.R. § 46.107(a) (1998).
14. See id §§ 46.107(a), 46.107(b).
15. See id. § 46.107(a); see infra Part I.B.1.
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cern" is scientific, and at least one whose is not.' 6 Finally, there must be
at least one person who is unaffiliated with the institution. 17 Given the
flexibility of these guidelines, the composition and internal workings of
IRBs vary immensely from institution to institution.1
8
2. Substantive Limitations on the Types of Research that Will Be
Approved
Before approving any research the IRB must conclude that the risks to
human subjects are acceptable. The research must employ procedures to
minimize any risk that does exist.' 9 Moreover, the research must not be
approved unless the risks are reasonable when weighed against the an-
ticipated benefits to the subjects and the importance of the knowledge
that could be gained from the research.2 ° More specific, and more strict,
rules limit the types of research that may be conducted on "vulnerable"
populations such as pregnant women, fetuses, children, and prisoners.
21
3. Ensuring the Informed Consent of Research Subjects
Historical abuses have exposed the potential for human experimenta-
tion to exploit the vulnerable and defenseless. 22 At the same time, hu-
man experimentation is critical to the development of new treatments
16. See 45 C.F.R § 46.107(c).
17. See id. §46.107(d).
18. See THE PRESIDENT'S ADVISORY COMMITTEE, THE HUMAN RADIATION
EXPERIMENTS: FINAL REPORT OF THE PRESIDENT'S ADVISORY COMMITTEE 543-48
(statement by Jay Katz) (1996); see also generally BRADFORD H. GRAY, HUMAN
SUBJECTS IN MEDICAL EXPERIMENTATION: A SOCIOLOGICAL STUDY OF THE
CONDUCT AND REGULATION OF CLINICAL RESEARCH (1975).
19. See 45 C.F.R. § 46.11 1(a)(1) (1998).
20. See id. §46.11 (a)(2).
21. See infra Part I.B.2. A revision of this policy is currently under considera-
tion; if adopted, pregnant women would no longer be considered "vulnerable" un-
der the regulations. See Protection of Human Research Subjects, 63 Fed. Reg.
27,793-95 (May 20, 1998); SUGARMAN ET AL., supra note 8, at 153.
22. See Patricia A. King, Race, Justice, and Research, in BEYOND CONSENT:
SEEKING JUSTICE IN RESEARCH 96-99 (Jeffrey Kahn et al. Eds., 1998) (discussing
the Tuskegee Syphilis Study); PRESIDENT'S ADVISORY COMMITTEE, supra note 18,
at 273-75 (discussing abuses involving prisoners); Henry K. Beecher, Ethics and
Clinical Research, 274 NEW ENG. J. MED. 1354, 1354 (1966) (providing one of the
first documentations of post-World War II abuses in the United States); see gener-
ally JAY KATZ, EXPERIMENTATION WITH HUMAN BEINGS (1972) (providing
throughout numerous examples of unethical experimentation on humans).
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and therapies for human ailments. These competing concerns ultimately
were balanced - and human experimentation legitimated - through the
doctrine of informed consent. The doctrine holds that experiments
should be conducted on human beings only if they freely consent after
being provided with all of the information relevant to the decision.23 In
this way, human experimentation, with its concomitant benefits, could
proceed with little risk that historical abuses would be repeated.
Accordingly, before an IRB approves research, it must find that the
researchers will seek the legally effective informed consent of
subjects.24 Researchers must give subjects "sufficient opportunity to
consider whether or not to participate [and] minimize the possibility of
coercion or undue influence.,, 25 Relevant information must be communi-
cated to the subject in plain language, and researchers may not seek
waivers of liability for negligence. 26 To satisfy the basic elements of
informed consent, researchers must disclose that the study involves re-
search;27 describe the procedures to be followed, the expected risks and
discomforts to the subject, and any anticipated benefits; and explain any
alternative courses of treatment that might be beneficial.28
To understand the protections that the regulations provide to vulner-
able populations, 29 two elements of informed consent must be consid-
ered separately: voluntariness and information. These concerns play
different roles in different contexts. Both prisoners and children, for
23. See LEVINE, supra note 9, at 96-153. The Nuremberg Code explains in-
formed consent as follows:
The voluntary consent of the human subject is absolutely essential.
This means that the person involved should have legal capacity to
give consent; should be so situated as to be able to exercise free
power of choice, without the intervention of any element of force,
fraud, deceit, duress, over-reaching or other ulterior form of con-
straint or coercion; and should have sufficient knowledge and com-
prehension of the elements of the subject matter involved as to en-
able him to make an understanding and enlightened decision.
Id. at 98.
24. See45 C.F.R. § 46.111(a)(3)(1998).
25. Id. §46.116.
26. See id.
27. This requirement recognizes that patient-subjects often will presume that
they are being treated, not studied. See infra Part II.A.6.
28. See 45 C.F.R. § 46.116(a) (1998) ("Basic elements of informed consent").
In addition, the regulations provide a number of other requirements of informed
consent, some of which apply only in special situations. See 45 C.F.R. §§
46.116(a)(5)-(8), 46.116(b)-(f), 46.117 ("Documentation of informed consent").
29. See infra Part I.B.
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example, are considered "vulnerable" populations that are entitled to
extra procedural safeguards before any research can go forward. 30 But
different concerns underlie these protections. With prisoners, the con-
cern is that their consent cannot be given voluntarily due to the inher-
ently coercive nature of the prison environment. With children, the con-
cern is whether they can sufficiently understand information in order to
make a rational decision about whether to participate in research. With
the terminally ill, both concerns may be present.
31
B. Additional Protections for "Vulnerable" Populations
The regulations contain a number of general provisions designed to
protect any human subject who may be vulnerable to coercion or undue
influence. In addition, there are specific provisions regulating research
involving pregnant women, fetuses, in vitro fertilization, children, and
prisoners. Essentially, the regulations provide three types of protections:
(1) structural provisions governing how IRBs will be comprised and
who will make decisions, (2) substantive provisions governing what
types of research will be allowed, and (3) procedural provisions to en-
sure that no research is done without the voluntary and informed consent
of the human subjects.
1. General Provisions Applicable to All Research
32
The regulations use but do not define the term "vulnerable." 33 Instead,
the regulations give examples of the types of subjects who are vulner-
able, and implicitly empower IRBs to assess the vulnerability of types of
subjects not listed. 34 Even when the current regulations were first pro-
posed after an exhaustive analysis of the then-existing regulatory
scheme, neither the Department of Health and Human Services (HHS)
30. See infra Part I.B.2.
31. See infra Part 11.
32. The term "all research" refers to all research to which the regulations ap-
ply. Although the reach of the regulations is extremely broad, there is some re-
search in the United States involving human subjects that continues to escape the
net of federal regulation. See 45 C.F.R. § 46.101 (1998) ("To what does this policy
apply?").
33. See 45 C.F.R. § 46.102 (failing to define the terms "vulnerable" or "vul-
nerable category of subjects"); see also 45 C.F.R. §§ 46.107 (governing the compo-
sition of IRBs), 46.111 (a)(3) (listing criteria for research approval), and 46. 111 (b)
(requiring additional safeguards when coercion is likely).
34. See, e.g., 45 C.F.R. § 46.107.
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nor the President's Commission for the Study of Ethical Problems in
Medicine and Biomedical and Behavioral Research provided any spe-
cific criteria with which to define vulnerable populations.
35
Structurally, vulnerable subjects are protected by encouraging repre-
sentation of their interests on the IRBs. Section 107 of the model federal
policy states that
if an IRB regularly reviews research that involves a vulnerable
category of subjects, such as children, prisoners, pregnant
women or mentally disabled persons, consideration shall be
given to the inclusion of one or more individuals who are
knowledgeable about and experienced in working with these
subjects. 6
The presence of vulnerable populations as research subjects also may
affect the types of research that are approved. Before an IRB may ap-
35. See PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN
MEDICINE AND BIOMEDICAL AND BEHAVIORAL RESEARCH, IMPLEMENTING HUMAN
RESEARCH REGULATIONS 23 (1983) [hereinafter COMMISSION REPORT]. The report
does not define the term "vulnerable," but perhaps implies that the ability to give
legal informed consent is the appropriate criterion to assess vulnerability. The
report states:
Ethical concerns about [children and the mentally disabled] revolve
around the issue of informed consent. Children, because of their
age, are generally unable to provide legally effective informed con-
sent. Those institutionalized as mentally disabled may or may not
be able to give informed consent or their capacity may fluctuate
over time.
Id.; see also Federal Policy for the Protection of Human Subjects, 53 Fed. Reg.
45,660, 45,666-67 (1988) (proposed Nov. 10, 1988) (discussing the effects of a
proposed change with regard to representation of vulnerable persons on IRBs, but
failing to define vulnerability).
36. 45 C.F.R. § 46.107(a) (1998). The previous version of this rule was more
strict. It required IRB representation whereas the current rule requires only con-
sideration of representation. See 45 C.F.R. § 46.107(a) (1985). HHS received a
number of comments arguing that this relaxation of the regulations would put vul-
nerable populations at risk. See Federal Policy for the Protection of Human Sub-
jects, 53 Fed. Reg. 45,660, 45,665 (1988) (proposed Nov. 10, 1988). The agency's
response underscores the critical role that IRBs play in the federal regulatory
scheme:
The Interagency Committee expects that institutions will use good
judgment and diligence in selecting persons as IRB members who
can fulfill the requirements of [section 107] . . .. In approving as-
surances the Federal Departments and Agencies that conduct, sup-
port, or regulate the research will review IRB composition to ensure
that the membership is appropriate.
Federal Policy for the Protection of Human Subjects, 53 Fed. Reg. 45,660, 45,665-
66.
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prove research, it must determine that the selection of subjects is equita-
ble. 37 In making this determination, the IRB "should be particularly cog-
nizant of the special problems of research involving vulnerable popula-
tions, such as children, prisoners, pregnant women, mentally disabled
persons, or economically or educationally disadvantaged persons.
38
Finally, research involving vulnerable populations receives height-
ened scrutiny to ensure the informed consent of the subjects. Before
approving a protocol involving subjects "likely to be vulnerable to coer-
cion or undue influence, such as children, prisoners, pregnant women,
mentally disabled persons, or economically or educationally disadvan-
taged persons," the IRB must ensure that "additional safeguards have
been included in the study to protect the rights and welfare of these
subjects. 39
2. Additional Protections for Particular Vulnerable Classes
The regulations create additional structural protections for certain
vulnerable classes. First, for research involving pregnant women, fe-
tuses, and human in vitro fertilization,40 one or more "ethical advisory
boards" is authorized to render advice as to whether certain types of
research are ethical. 4' The ethical advisory boards do not have any inde-
pendent power to limit the types of research that can be done; rather,
they are authorized to provide advice to HHS before certain types of
research are approved.42 Second, for research involving prisoners, a
majority of the IRB members must have no association with the prison
from which the human subjects are selected, and at least one member of
the IRB (or IRBs, if more than one reviews the research) must be a pris-
oner or "prisoner representative with appropriate background and expe-
37. See45 C.F.R. § 46.111(a)(3)(1998).
38. Id.
39. Id.
40. See 45 C.F.R. pt. 46, subpt. B ("Additional Protections Pertaining to Re-
search, Development, and Related Activities Involving Fetuses, Pregnant Women,
and Human In Vitro Fertilization"). These rules predate the model rule and apply
only to HHS-sponsored activities. See 45 C.F.R. § 46.201.
41. See 45 C.F.R. § 46.204 (1998). No ethical advisory boards are currently
constituted. Interview with Anna C. Mastroianni, Assistant Professor, University
of Washington School of Law and the Public Health Genetics Program, Seattle,
WA (Oct. 9, 1998).
42. See 45 C.F.R. § 46.204(c).
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"43rience. ' 4
Substantively, there are also significant limitations on the types of
research that may be conducted. For research involving pregnant women
or fetuses, unless the research is designed to meet the health needs of the
mother or the fetus, the IRB should not approve it if it involves more
than minimal risk to the fetus.A4 The IRB also should not approve such
research if appropriate studies have not already been completed on ani-
mals and non-pregnant persons.45
Restrictions on research involving prisoners are even more strict.
46
Researchers may examine the causes, effects, and consequences of in-
carceration or criminal behavior;47 prisons as institutions;4 conditions
such as drug addiction that affect prisoners as a class; 49 and methods of
43. Id. § 46.304.
44. Id. §§ 46.206-46.208.
45. See 45 C.F.R. § 46.206(a)(1).
46. See 45 C.F.R. § 46.306 (1998). The regulations governing the use of pris-
oners as research subjects, 45 C.F.R. pt. 46, subpt. C, are very restrictive and reflect
a basic presumption that any "consent" they give to participate in research is inher-
ently suspect due to their incarceration. See 45 C.F.R. § 46.302 (1998) ("Inas-
much as prisoners may be under constraints because of their incarceration which
could affect their ability to make a truly voluntary and informed decision whether
or not to participate as subjects in research, it is the purpose of this subpart to pro-
vide additional safeguards for the protection of prisoners."). This suspicion is, of
course, warranted and a natural response to the notorious experiments conducted by
Nazi doctors during World War II. These so-called experiments have been ex-
haustively documented and discussed elsewhere, beginning with the Nuremberg
trials. See generally ROBERT J. LIFTON, THE NAZI DOCTORS: MEDICAL KILLING
AND THE PSYCHOLOGY OF GENOCIDE (1986); CLAUDE J. LETULLE, NIGHTMARE
MEMOIRE: FOUR YEARS AS A PRISONER OF THE NAZIS (1987) (recounting the per-
sonal experiences of a prisoner who was forced to assist in Nazi experiments on
humans); GERALD L. POSNER & JOHN WARE, MENGELE: THE COMPLETE STORY
(1986) (recounting in detail experiments conducted by Josef Mengele at the
Auschwitz concentration camp between 1943 and 1945). Experimental abuses
involving prisoners are by no means confined to the Nazis. See KATZ, supra note
22, at 1013-52 (discussing case studies of a variety of experiments on prisoners,
many of which were conducted in the United States after World War II). Interest-
ingly, however, the regulations primarily respond to this concern not by imposing
procedural safeguards, but rather by tacitly creating an irrebuttable presumption
that prisoners cannot give their informed consent to participate in most types of
research.
47. See 45 C.F.R. § 46.306(a)(2)(i).
48. See id § 46.306(a)(2)(ii).
49. See id. § 46.306(a)(2)(iii).
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improving the health or well-being of the prisoners. 50 No other research
may use prisoners as human subjects. 51
There are also substantive restrictions on the types of research that
may be conducted on children. 52 If the risk to the child subjects is mini-
mal, research may be approved if the requirements of informed consent
are met for both parents and child.13 Research likely to yield generaliz-
able knowledge that is "vital to the understanding or amelioration of the
subjects' disorder or condition" may be conducted if the risk "represents
a minor increase over minimal risk. 54 If greater risk is involved," the
research must be intended to benefit the subject, the risk must be "justi-
fied" by the benefit, and the risk/benefit ratio of the experimental ther-
apy must be at least as favorable as that provided by available alterna-
tive approaches. 56 IRBs may not approve research that fails to meet
these requirements unless the Secretary of HHS makes an exception
after finding that: (1) the research presents an opportunity to understand
a serious health problem facing children; and (2) the research will be
conducted ethically.
57
The regulations also impose further procedural safeguards to ensure
that certain vulnerable research subjects do not participate without pro-
viding their fully informed consent. For research involving pregnant
50. See id. §46.306(a)(2)(iv).
51. See 45 C.F.R. § 46.306(b).
52. See 45 C.F.R. §§ 46.404-46.406. Like prisoners, children historically have
fallen victim to a wide variety of experimental abuse. See Ross G. Mitchell, The
Child and Experimental Medicine, 1 BRIT. MED. J. 722, 725-26 (1964), reprinted
in KATZ, supra note 22, at 963-64. Orphans, or "foundlings," were frequently used
as research subjects with little or no thought to whether they had given their con-
sent, and even the children of the researchers were sometimes used. See id. (dis-
cussing an 1894 experiment in which the researcher injected his son with a "crude
extract of endocrine glands").
53. See 45 C.F.R. § 46.404 (1998).
54. Id. § 46.406 (1998). Minimal risk "means that the probability and magni-
tude of harm or discomfort anticipated in the research are not greater in and of
themselves than those ordinarily encountered in daily life or during the perform-
ance of routine physical or psychological examinations or tests." Id. §46.102(i).
55. That is, any risk greater than "a minor increase over minimal risk." Id §
46.406(a).
56. See id. §46.405.
57. See 45 C.F.R. § 46.407. Additional requirements are imposed when the
potential research subjects are wards of the state. See 45 C.F.R. § 46.409.
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women 58 and fetuses,59 the regulations suggest that the informed consent
requirement is met if members of the IRB or "subject advocates" (1)
participate in or at least carefully monitor the informed consent proce-
dures, and (2) monitor or evaluate the research itself to determine
whether any unanticipated risks to the subjects arise. 60 Also, to prevent
undue influence, researchers cannot influence abortion decisions, 61 de-
termine the viability of a fetus at the termination of a pregnancy,62 or
offer monetary or other incentives to terminate pregnancies for purposes
of the research. 63 For research involving prisoners as subjects, IRBs may
approve research only if: (1) the researchers do not provide inappropri-
ate incentives to participate, such as better living conditions, food, or
amenities; (2) the risks of participation would be acceptable to a non-
prisoner volunteer; (3) the subjects are selected fairly; (4) relevant in-
formation is presented in comprehensible language; and (5) the prison-
ers' participation does not affect parole decisions.64 Finally, when chil-
dren are used as research subjects, their parents must provide their in-
formed consent, 65 and the children themselves generally must "assent"
66to participation.
58. See 45 C.F.R. § 46.207 (1998).
59. See id § 46.208.
60. See id. § 46.205(a)(2). This Article argues that similar safeguards should
be employed to protect the terminally ill from coercion and undue influence. See
infra Part ill.
61. See id § 46.206(a)(3)(i).
62. See 45 C.F.R. § 46.206(a)(ii).
63. See id § 46.206(b).
64. See id. § 46.305(a).
65. See id. §§ 46.116 (general requirement of legally effective informed con-
sent), 46.408(b), 46.408(c). There are, however, a number of caveats and qualifi-
cations to this rule. See id. §§ 46.408(b), 46.408(c).
66. See 45 C.F.R. § 46.408(a). Exceptions to this rule apply when the IRB
determines that because of age, maturity, or psychology, the child-subject is inca-
pable of assenting, or if the IRB determines that the research "holds out a prospect
of direct benefit that is important to the health or well-being of the [child] and is
available only in the context of research." Id. Thus, in at least some circumstances
- so long as legally effective parental consent is obtained - the regulations tacitly
authorize research involving child subjects against their will.
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3. The Terminally Ill as a "Vulnerable" Population?
Commentators have long recognized that the terminally ill share some
of the characteristics of "vulnerable" populations such as children and
prisoners. "[L]ike children, their ability to make informed decisions is
often either impaired or disregarded, and, like soldiers and prisoners,
they are . . . 'captives' of their disease, their physicians and hospital, and
their enforced isolation. ''67 Yet current federal regulations provide no
explicit protections for the terminally ill beyond those required when-
ever a human subject is employed in an experiment.68
The terminally ill, unlike prisoners, children, pregnant women, and
fetuses, have no dedicated regulations to ensure that they are not vic-
timized in unethical research. Thus, if they are entitled to any regulatory
protection, it must be found in the general regulations applicable to all
"vulnerable" populations. 69 It is unclear whether and to what extent
these rules apply.70 On the one hand, the relevant regulatory provisions
and the official government publications neither list nor discuss the ter-
67. KATZ, supra note 22, at 1053; see also LEVINE, supra note 9, at 77-79;
JONI N. GRAY ET AL., ETHICAL AND LEGAL ISSUES IN AIDS RESEARCH 52 (1995)
("To be sure, research participants with fatal illnesses are vulnerable in many
ways").
68. See 45 C.F.R. pt. 46 (1998). However, the terminally ill were mentioned as
a potentially incompetent group in the Belmont Report, which served as the basis
for the current federal regulations. THE NATIONAL COMMISSION FOR THE
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH,
THE BELMONT REPORT 13 (1978) [hereinafter THE BELMONT REPORT] ("Each class
of subjects that one might consider incompetent (e.g., infants and young children,
mentally disabled patients, the terminally ill and the comatose) should be consid-
ered on their own terms").
69. These provisions encourage IRBs to include members of vulnerable popu-
lations if the IRB works with those populations, requires "equitable" selection of
subjects considered in light of their "vulnerability," and requires additional safe-
guards to prevent coercion and undue influence. See supra Part I.B. 1.
70. This discussion is relevant only to the terminally ill who are legally com-
petent adults. Whether a terminally ill person who has been judged legally incom-
petent can participate in research is determined by whether his or her legally
authorized representative consents. See 45 C.F.R. § 46.116. Similarly, children are
already entitled to substantial protection under separate regulations. See 45 C.F.R.
§§ 46.407-46.409; see also supra Part I.B.2.
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minally ill as a vulnerable population.7' Moreover, labeling the termi-
nally ill as vulnerable would further stigmatize people already suffering
greatly from loss of personal autonomy and dignity.7 2 Accordingly, an
IRB could, consistent with federal regulations, conclude that the termi-
nally ill were not vulnerable.
On the other hand, the regulations leave the term "vulnerable" unde-
fined and open-ended.73 When examples of vulnerable populations are
provided, the lists vary from provision to provision, strongly suggesting
that the types of populations listed were meant to be illustrative, rather
than denominative. If, as this Article argues, 74 the terminally ill share a
number of relevant characteristics with the vulnerable populations listed
in the regulations, an IRB would be well within its authority to treat the
terminally ill as vulnerable. Indeed, a number of commentators seem to
assume that the terminally ill are considered a vulnerable population
under the regulations.75
The most that can be said with any certainty, however, is that the
regulations leave the assessment of vulnerability of the terminally ill to
the IRBs. Thus, in some cases the regulatory protections may apply, and
in other cases they may not.
C. The Call for Fewer Regulatory Restrictions on Research
Involving the Terminally Ill
The terminally ill have long been the subject of both formal and in-
formal research that has yielded many important medical advances. In
recent years, however, the terminally ill have not sought regulatory
protection. On the contrary, generally they are not only willing to par-
71. See, e.g., 45 C.F.R §§ 46.101-46.409; see generally, e.g., PRESIDENT'S
COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND
BIOMEDICAL RESEARCH, IMPLEMENTING HUMAN RESEARCH REGULATIONS: THE
ADEQUACY AND UNIFORMITY OF FEDERAL RULES AND OF THEIR IMPLEMENTATION
(1983); FOOD AND DRUG ADMINISTRATION, CURRENT ISSUES IN HUMAN SUBJECT
PROTECTION (1996). But see THE BELMONT REPORT, supra note 68, at 13 (stating
that the terminally ill may be considered "incompetent").
72. See infra Part II.A.
73. See 45 C.F.R. §§ 46.107(a), 46.11 1(a)(3), 46.11 1(b)(1998).
74. See infra Part II.
75. See, e.g., GRAY ET AL., supra note 67, at 31-32 (assuming that IRBs are
required under 45 C.F.R. § 46.11 l(b) to ensure that additional safeguards are in
place for AIDS patients, and that at least for IV drug users with AIDS, the IRBs
would be required to include an advocate for those individuals on the IRB).
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ticipate in research, but they often compete vigorously for the opportu-
nity to do so, believing that experimental therapies offer their only hope
of survival.7 6 With the emergence of AIDS in the 1980s, political activ-
ists successfully channeled these concerns and eliminated some of the
regulatory safeguards impeding the availability of new treatments.77
Unlike the general HHS regulations, which have no exceptions to fa-
cilitate research involving the terminally ill,78 the Food and Drug Ad-
ministration (FDA) has adopted a number of specific regulations to al-
low for faster approval and distribution of experimental drugs. 79 Gener-
ally, before a new drug can be prescribed, it must gain FDA approval,
which requires the completion of three successive phases of human
testing.80 In Phase I, a small number of healthy subjects receive the drug
and are monitored for side effects to determine whether the drug is
safe.8' In Phase II, the drug is tested on a slightly larger population of
infected or symptomatic individuals.8 2 If the results of Phase II are
promising, Phase III testing is done on a larger sample to further exam-
ine the efficacy of the drug.83 Following Phase III, the researchers may
submit an application to the FDA to have the drug approved for wide-
spread use. 4
Patients with "life-threatening or seriously debilitating illnesses" may
76. See TIME Special Report, supra note 2, at 38-51.
77. See Lisa Terrizzi, The Need for Improved Access to Experimental Drug
Therapy: Aids Activists and Their Call for a Parallel Track Policy, 4 ADMIN. L.J.
589, 589 (1991); Daugherty et al., supra note 6, at 894 (noting that AIDS activists
argued that the goal of regulation "should be to maximize patient opportunity and
choice to participate in clinical research rather than to maximize patient safety").
78. See 45 C.F.R. §§ 46.101-46.409 (1998).
79. See 21 C.F.R. pt. 312 (1998) (Investigational New Drug Application), sub-
part E (Drugs Intended to Treat Life-threatening and Severely Debilitating Ill-
nesses), §§ 312.80-312.88 (1998); 21 C.F.R. pt. 314 (Applications for FDA Ap-
proval to Market a New Drug or an Antibiotic Drug), subpt. H (Accelerated Ap-
proval of New Drugs for Serious or Life-Threatening Illnesses), §§ 314.500-
314.560; 21 C.F.R. pt. 601 (Licensing), subpt. E (Accelerated Approval of Biologi-
cal Products for Serious or Life-Threatening Illnesses), §§ 601.40-601.46.
80. See id, at pt. 312. Subsequent to FDA approval, Phase IV studies are




83. Seeid. § 312.22(c).
84. See 21 U.S.C. § 355(b)(Supp. 1998).
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gain more rapid access to new drugs in two ways.8 5 First, physicians can
now prescribe drugs that are being tested in Phase II to the terminally ill
if no adequate alternative therapy is available and the drug sponsor is
making a diligent effort to have the FDA approve the drug.8 6 Second, for
drugs intended to treat life-threatening or seriously debilitating illnesses,
the drug sponsor can seek "fast-track" approval, whereby the FDA may
approve the drug without Phase III testing.
8 7
As regulatory hurdles have been lowered and potentially life-saving
new therapies made more widely available, some physicians and re-
searchers have begun "to reconsider the 50-year-old Nuremberg para-
digm that participants in human research are ignorant and vulnerable
and must be protected."88 A recent article calls for abandonment of pa-
ternalistic attitudes toward research on the terminally ill, noting that the
modern environment is radically changed:
Before the emergence of AIDS and its effect on clinical trials
and drug development, clinical research was perceived as a pro-
cess of human experimentation that sometimes involved cruel,
even inhumane, treatment. Today, clinical trials and access to
the drug development process are viewed as valuable societal
goods and rights that should be guaranteed. 9
This paradigm shift, however, may be problematic. The terminally ill
have lobbied successfully for the right to decide which drugs to take to
treat their illnesses, arguing that paternalistic regulation is unnecessary
because they are not vulnerable. The goal of deregulating access to
drugs is laudable, but based on a false premise. That is, terminally ill
patients should have the right to make intimate, personal decisions about
their course of treatment, but they are also vulnerable to abuse when
they participate in human research. 90
85. For an excellent summary of the historical development of these regulatory
reforms to speed up access to investigation drugs for the terminally ill, see Steven
R. Salbu, Regulation of Drug Treatments for HIV and AIDS: a Contractarian
Model ofAccess, 11 YALE J. ON REG. 401, 410-17 (1994).
86. See 21 C.F.R. § 312.34(b)(1)(i)-(iv) (1998).
87. Seeid §312.80.
88. Daugherty et al., supra note 6, at 892 (citing THE BELMONT REPORT, supra
note 68).
89. Id.
90. See id. (arguing that "[a] more informed and meaningful dialogue between
investigators and patients who have terminal illnesses would recognize patients'
vulnerability but also their autonomous decision-making ability").
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II. THE VULNERABILITY OF THE TERMINALLY ILL
Many factors contribute to the vulnerability of the terminally ill. Indi-
viduals' psychological responses to terminal illness vary widely. Some
employ healthy coping mechanisms, but many suffer from a variety of
psychological problems - such as acute anxiety, depression, anger, and
dependency - that can make it difficult, if not impossible, to rationally
evaluate the pros and cons of participating in potentially life-threatening
research. In addition, tremendous financial and professional rewards for
discovering new treatments and publishing the results provide a strong
incentive for researchers to bend or break the rules. As a result, the ter-
minally ill patient considering whether to participate as a research sub-
ject is highly vulnerable to coercion and undue influence.
A. Psychological Manifestations of Terminal Illnesses and the
Effect on Decision-making Capacity
Being diagnosed with a terminal illness often initiates a profound psy-
chological response in patients and sometimes causes a variety of psy-
chopathologies. Psychological symptoms may be exacerbated by the
physiological symptoms of the disease. Further, patients may be reluc-
tant to question the authority of their physicians. Working together,
these factors may limit the terminally ill patient's ability to engage in
autonomous, rational decision-making.
1. "Normal" Psychological Responses to Terminal Illness
Psychologists have not reached consensus regarding the emotional
and psychological processes that normally occur upon being diagnosed
with a terminal illness. Freud hypothesized that the general human fear
of death was rooted in a fear of the unknown.9 ' Others have argued that
"death anxiety does not pertain to physical death, but to the primordial
feelings of helplessness and abandonment. The fear of the unknown of
death is the fear of the unknown of annihilation of self, of being, of
identity." 92
Regardless of the source of humans' fear of death, most experts seem
to agree that people live most of their lives in a state of denial about
91. See generally Sigmund Freud, Thoughts for the Times on War and Death,
in SIGMUND FREUD, 4 COLLECTED PAPERS (1915).
92. E. Mansell Pattison, The Living-Dying Process, in PSYCHOSOCIAL CARE OF
THE DYING PATIENT 133-34 (Charles A. Garfield ed., 1978).
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their own mortality, largely ignoring the reality of death except when
forced to confront it.93 Denial is generally viewed as a healthy coping
mechanism.94 Diagnosis with terminal illness, however, makes death
imminent and often forces patients to come to terms with their formerly
suppressed anxieties and fears.
95
While recognizing that individuals employ a wide variety of coping
mechanisms and thus handle terminal illnesses in different ways, psy-
chologists have identified three phases through which the terminally ill
typically pass: acute, chronic, and terminal.96 In the acute phase, brought
on by the diagnosis of terminal illness, the patient may experience pro-
97found emotional turmoil and severe anxiety. The diagnosis presents a
problem that cannot be solved, and the patient is forced to try to assimi-
late the new information and fundamentally restructure his or her views
of life and death. 9
The crisis of diagnosis also may trigger latent psychological problems
of "dependency, passivity, narcissism, identity ...[o]ne is faced not
only with the immediate dying process but also with the unresolved
feelings from one's own lifetime and its inevitable conflicts." 99 Some
may respond initially with "immobilization," unable to react to the crisis
93. See generally ERNEST BECKER, THE DENIAL OF DEATH (1973).
94. See id.
95. See Pattison, supra note 92, at 134 (discussing a number of earlier studies).
96. See Kennneth J. Doka, When Illness is Prolonged: Implications for Grief,
in LIVING WITH GRIEF WHEN ILLNESS IS PROLONGED 6-7 (Kenneth J. Doka &
Joyce Davidson eds., 1998) [hereinafter LIVING WITH GRIEF]; ELISABETH KOBLER-
Ross, ON DEATH AND DYING (1969).
Elisabeth Kilbler-Ross argued in her seminal work, ON DEATH AND DYING, that
patients progress through a series of six set stages: first shock, then denial, anger,
bargaining, depression, and finally acceptance. See KOBLER-ROSS, supra. Modem
theory acknowledges that these psychological responses to terminal illness are
common, but rejects the thesis that patients progress in a linear manner through
each of the stages. See Charles A. Garfield, Elements of Psychosocial Oncology:
Doctor-Patient Relationships in Terminal Illness, in PSYCHOSOCIAL CARE OF THE
DYING PATIENT, supra note 92, at 103; Pattison, supra note 92, at 133-34 (noting,
however, that there are phases where certain psychological responses are seen most
frequently: the acute diagnosis phase, the chronic living-dying phase, and finally
the terminal phase immediately preceding death).
97. See Doka, supra note 96, at 7.
98. See Pattison, supra note 92, at 145-46.
99. Id.
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because they feel as though it is not happening to them.'00 Many experi-
ence "an overwhelming, insuperable feeling of inadequacy-a potential
dissolution of the self. There is bewilderment, confusion, indefinable
anxiety, and unspecified fear."' '
In the chronic phase, the initial crisis of diagnosis has subsided, but
the patient nevertheless must contend with the physical deterioration
that accompanies a terminal illness. Additionally, the patient must con-
tinue to cope with the knowledge of impending death. In some patients,
there may be a recovery phase, if, for example, there is a remission of
the illness. Finally, the terminal phase constitutes the physical process of
dying.
10 2
Depending on the patient, the psychological trauma of terminal illness
manifests in many different ways. Some patients persistently deny to
themselves and others that they have an illness at all.'0 3 Others respond
primarily with anger, blaming themselves, others, and even their genetic
ancestors for their illness. 10 4 The anger response can tend to alienate
medical personnel and make communication more difficult.'0 5 Often,
terminally ill patients become depressed, withdrawing from their support
network and losing the will to live. 06 Another common response is la-
100. See id.
101. Id. (citing R. Noyes Jr. & R. Kletti, Depersonalization in the Face of Life-
Threatening Danger: A Description, 39 PSYCHIATRY 19, 19 (1976)).
102. See Doka, supra note 96, at 6-7.
103. See PSYCHIATRIC CARE OF THE MEDICAL PATIENT 5 (Alan Stoudemire &
Barry S. Fogel eds., 1993)[hereinafter PSYCHIATRIC CARE]; SHARON L. ROBERTS,
BEHAVIORAL CONCEPTS AND THE CRITICALLY ILL PATIENT 197-222 (2d ed. 1986)
(noting that denial manifested itself on a continuum ranging from rationalization to
"magical thinking" to complete withdrawal from reality, and discussing a number
of case studies where patients persistently refused to acknowledge their serious
illnesses or alter their behavior accordingly); see also Orville Eugene Kelly, Living
with a Life-Threatening Illness, in PSYCHOSOCIAL CARE OF THE DYING PATIENT,
supra note 92, at 51-68 (discussing author's personal response to cancer diagnosis,
and noting that he wondered "whether a mistake had been made; maybe [he] didn't
have cancer at all").
104. See PSYCHIATRIC CARE, supra note 103, at 6; ROBERTS, supra note 103, at
197-222; see also Garfield, supra note 96, at 103.
105. See ROBERTS, supra note 103, at 197-222. See also Garfield, supra note
96, at I ll.
106. See PSYCHIATRIC CARE, supra note 103, at 6; ROBERTS, supra note 103, at
197-222. Feelings of loneliness and isolation may exacerbate this problem. See id.
at 223-51; see also Kelly, supra note 103, at 59-68 (after being diagnosed with
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beled "dependency." Because the illness limits the patient's autonomy
and control over his life, he may become child-like, regressing back to
"passive behaviors characteristic of early developmental phases" of
life. 07 Perhaps the most pervasive response is anxiety. "The onset of
illness is always accompanied by heightened anxiety, as the patient
questions the extent and degree of the particular ailment."'
08
In cancer patients, even among mentally healthy patients, hopeless-
ness, anxiety, and fear are normal responses. The universal fears of can-
cer patients have been dubbed the six Ds: death, dependency, disfigure-
ment, disability interfering with normal life functions, disruption of re-
lationships, and discomfort or pain resulting from the disease itself.'0 9
How well the patient copes with these fears is a function of a variety of
factors: (1) the nature and progression of the disease itself; (2) the pa-
tient's level of psychological adjustment prior to onset of the disease;
(3) the extent to which the disease threatens to impair the normal activi-
ties of the patient; (4) the culture and religion of the patient; (5) the pa-
tient's support network; (6) the patient's potential for rehabilitation; and
(7) the patient's personal style for coping. 110 In critically ill patients,
similar psychological reactions are seen."
2. Psychological Disorders Among the Terminally Ill
The terminally ill often suffer from a variety of psychological ail-
ments that frequently are never diagnosed or treated." 2 For example, in
a significant percentage of cancer patients the illness induces diagnos-
able psychiatric disorders. In one study, where 215 cancer patients at
cancer, author notes as follows: "I was very depressed. I began to isolate myself
from everyone. Much of the time I spent in bed.... My family was falling apart.
Communications had nearly stopped."); Garfield, supra note 96, at 104 (noting that
preparatory depression, i.e., depression caused by anticipated loss of one's body,
and relationships with others, often manifests itself in "frightening dreams, irrita-
bility, extreme sadness, anorexia, and apathy").
107. See PSYCHIATRIC CARE, supra note 103, at 7.
108. Id.
109. See Lynna M. Lesko et al., Oncology, in PSYCHIATRIC CARE, supra note
103, at 565.
110. See id.
111. See ROBERTS, supra note 103, at 197-222 (noting that critically ill patients
frequently suffer from sleep deprivation, hopelessness, anger or hostility, avoidance
or denial, feelings of powerlessless, loneliness, and depression).
112. See generally PSYCHIATRIC ASPECTS OF TERMINAL ILLNESS (Samuel C.
Klagsbrun et al., eds., 1988)[hereinafter PSYCHIATRIC ASPECTS].
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three major cancer centers were selected at random, forty-seven percent
of the patients suffered from psychiatric disorders. 1 3 Of the patients
with disorders, sixty-eight percent had "adjustment disorder with de-
pressed, anxious, or mixed mood; 13% had major depression; 8% had an
organic mental disorder; 7% had a personality disorder; and 4% had
anxiety disorder."' 14 Only eleven percent of these disorders existed prior
to disease or treatment.115 Other studies have indicated a similar preva-
lence of psychiatric disorders in cancer patients." 
6
3. Physiological Symptoms of Illness and Treatment That May Impair
Cognitive Function
Depending on the illness, the physiological symptoms of disease or its
treatments may directly impair cognitive function. With cancer, for ex-
ample, as one physician notes, "[flatigue, recovery from surgery and
radiation, [and] toxicity from drugs (including antibiotics and pain
medicine) may all alter thinking ability, dampening the sharpness, ra-
pidity, and productivity of the [patient's] thought processes.""' The loss
of mental functioning is more direct and obvious with Alzheimer's dis-
ease, where "physical death" often occurs well after what some have
referred to as psychological death." 8 Similarly, in AIDS patients, "be-
cause AIDS often involves degradation of mental processes, the ability
to give competent consent may be compromised."'" 9
In cardiac patients, a combination of physical and mental processes
often produces acute anxiety. With the onset of physical symptoms of
cardiac disease, such as angina and arrhythmias, patients experience
acute "anxiety related to fears of heart attacks, disability, and sudden
113. See Lesko et al., supra note 109, at 566.
114. Id.
115. See id.
116. See id. (citing J.B. Bukberg et al., Depression in Hospitalized Cancer Pa-
tients, 46 PSYCHOSOM. MED. 199 (1984) (finding that fifty-six percent of cancer
patients suffered from depression)).
117. Stephen P. Hersh, Death From The Cancers, in LIVING WITH GRIEF, supra
note 96, at 100.
118. See Carol Williams & Brenda Moretta, Systemic Understandings of Loss
and Grief Related to Alzheimer's Disease, in LIVING WITH GRIEF, supra note 96,
at 120 (citing D. COHEN & C. EISDORFER, THE LOSS OF SELF: A FAMILY
RESOURCE FOR THE CARE OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
(1986)).
119. GRAY ET AL., supra note 67, at 53.
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death."' 120 Patients "may fear annihilation or object loss, or may struggle
with feelings of passivity, impotence, or guilt ... [which are] magnified
by the acute autonomic and physiologic concomitants of acute cardiac
disease (cold sweats, nausea, light-headedness, shortness of breath,
chest tightness, etc.)9
121
The terminally ill patient who is hospitalized for a long period of time
also may experience physical and psychological responses to her envi-
ronment which further hamper her ability to make informed decisions.
Due to the unfamiliar environment and the increased sensory input of
the hospital, many patients suffer from sleep deprivation. 22 Sleep depri-
vation exacerbates the physical and emotional trauma of terminal illness,
and may lead to lassitude, lethargy, hallucinations, disorientation, con-
fusion, restlessness, irritability, apathy, poor judgment, memory distur-
bance, delusions, paranoid ideation, and hostility. 123 Patients also com-
monly experience extreme anxiety over seemingly routine matters such
as the prospect of being transferred from one room to another.
24
4. The Coercive Effect of Hospitalization
The terminally ill are frequently hospitalized. Thus, like prisoners,
who are dependent on their guards and other prison employees for their
daily needs as well as for their well-being, the terminally ill are often
completely dependent on the hospital's researchers and staff. As a re-
sult, patients actively seek to avoid upsetting the researchers and to
curry favor with them. Patients who respond with anger to their disease,
and who subjectively displace and direct such anger toward their doc-
tors, are nevertheless reluctant to express these feelings for fear of re-
taliation. 125 Also like prisoners, the terminally ill often have little control
120. James L. Levenson, Cardiovascular Disease, in PSYCHIATRIC CARE, supra
note 103, at 540.
121. Id.
122. See Roberts, supra note 103, at 63-94.
123. See id. at 68 (citing Jean Hayter, The Rhythm of Sleep, AM. J. NURSING
457, 457 (1980)); Gina Zelechowski, Sleep and the Critically Ill Patient, CRITICAL
CARE UPDATE, Feb. 1979, at 5; Luva Fabijan & Marie Gosselin, How to Recognize
Sleep Deprivation in Your ICU Patient and What to Do About It, CANADIAN
NURSE, Apr. 1982, at 21.
124. See Roberts, supra note 103, at 298-330.
125. See PRESIDENT'S ADVISORY COMMITTEE, supra note 18, at 472 (quoting a
research subject's feelings when deciding whether to undergo a bone marrow
transplant: "They were really pushing this procedure.... It was very obvious to me
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over their environment, which may further heighten anxiety.
26
5. Effect on Decision-making Capacity
The psychological manifestations of terminal illness may affect pa-
tients' ability to give informed consent in a variety of ways. 12 First,
they may impair cognitive function. 2  Research suggests that persons
suffering from depression have difficulty processing information and
reasoning.' 29 It seems likely that patients who react to their terminal ill-
nesses with extreme anxiety, anger, or denial would encounter similar
difficulties. In addition, even if cognitive abilities remain intact, depres-
sion may undermine the risk/benefit analysis on which the validity of
informed consent rests. Many researchers have suggested that depressed
persons would be less likely to consent to participate in research because
of pessimism, or a tendency to overestimate risk and underestimate
benefit. 30 In fact, the opposite may be true. Depressed persons may be
that they wanted people to sign up for this bad, and I did not want to upset my
doctor.... Y'know I'm totally helpless. I'm in his hands and, so part of it was, I
wanted to keep him happy and, uh, there was some pressure."); see also Roberts,
supra note 103, at 298-330 ("The individual may feel justified in his anger or hos-
tility, but he may not be able to demonstrate his anger overtly toward the staff. He
may fear that if he expresses outward anger toward his nurse or doctor, they may
retaliate by not providing him with care.").
126. See Roberts, supra note 103, at 298-330 (noting that patients feel powerless
because of loss of control over "admission procedures, the choice of doctor, deci-
sion-making ability, schedules, and routines." Even a dropped call light may result
in extreme anxiety. "The critically ill patient who is already in an anxiety crisis
may depend heavily upon the security of visual and verbal contact with his nurse.
Without such contact, he may feel overwhelming powerlessness and alienation.").
127. See generally NATIONAL BIOETHICS ADVISORY COMMISSION, RESEARCH
INVOLVING PERSONS WITH MENTAL DISORDERS THAT MAY AFFECT
DECISIONMAKING CAPACITY (December 1998) [hereinafter NBAC REPORT].
128. See id. at 7-8 (noting that the following conditions, which are often found
among the terminally ill, may affect cognitive function and decisionmaking capac-
ity: dementia associated with Alzheimer's disease, HIV infection, and neurological
conditions such as Parkinson's disease and Huntington's disease; delirium caused
by "systemic medical conditions, side effects of medications, or intoxication with
or withdrawal from psychoactive agents or toxins;" and depression).
129. See id. at 8 (citing Shirley Hartlarge et al., Automatic and Effortful Proc-
essing in Depression, 113 PSYCHOL. BULL. 247-48 (1993); Jane E. Baker & Shelly
Channon, Reasoning in Depression: Impairment on a Concept Discrimination
Learning Task, 9 COGNITION & EMOTION 579-97 (1995)).
130. See, e.g., Jan Marta, The PSDA and Geriatric Psychiatry: A Cautionary
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more likely to consent because the notion of risk is meaningless to
them. 3' In essence, they become malleable and vulnerable to coercion
precisely because they do not care whether they live or die.
Feeling desperate, terminally ill patients may fail to try to evaluate
risks and benefits at all, having already made up their minds to try any
available treatment. A May 1998 front page article in the New York
Times discussed the potential for angiostatin and endostatin as a cancer
treatment that works by cutting off the blood supply to the tumors. 32 Dr.
Judah Folkman, who discovered the drugs, stated that "he gets hundreds
of calls a day from cancer patients, pleading for the drugs."' 33 This oc-
curs despite the fact that the drugs have never been tested on human
beings, and neither the risks nor the benefits of the drugs are known.
This phenomenon thus inverts the roles of doctor and patient in in-
formed consent negotiations. Instead of the doctor seeking the consent
of the patient, the patient seeks the consent of the doctor to allow him to
participate.134 Orville Kelly, a cancer patient who started a support group
to help other cancer patients deal with the emotional trauma of their ill-
nesses, notes that once patients become desperate, "many seem willing
to try anything in the event that it might work. For them, false hope is
better than no hope at all.' 35
6. Therapeutic Misconception
Partly as a result of their desperation, terminally ill research subjects
often will completely fail to understand that they are participating in
Tale, 4 J. CLINICAL ETHICS 80, 80 (1993); Linda Ganzini et al., Do-not-resuscitate
Orders for Depressed Psychiatric Inpatients, 43 HosP. COMMUNITY PSYCHIATRY
915, 915 (1992); Mark D. Sullivan & Stuart J. Youngner, Depression, Competence,
and the Right to Refuse Life-saving Treatment, 151 AM. J. PSYCHIATRY 971, 971
(1994).
131. See generally Carl Elliott, Caring About Risks: Are Severely Depressed
Patients Competent to Consent to Research?, 54 ARCH. GEN. PSYCHIATRY 113
(1997) (arguing that the severely depressed persons may be incompetent to give
their informed consent because they do not care about risks and because they are
not authentically acting as themselves).
132. See Kolata, supra note 1, at Al.
133. Id.
134. Desperate terminally ill patients are also prone to try to convince their phy-
sicians to try so-called "alternative medicine" along with their normal course of
treatment. See Edmund D. Pellegrino, Emerging Ethical Issues in Palliative Care,
279 JAMA 1521, 1521 (1998).
135. Kelly, supra note 103, at 65.
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research that may not be intended primarily for their benefit. This phe-
nomenon has become known as "therapeutic misconception."' 13 6 The
patient-subject tends to pay little attention to written forms, 3 7 and more
careful informed consent procedures may be equally impotent. One
study examined the motivation and understanding of patients partici-
pating as subjects in Phase I cancer research. 38 The study found that
patients were motivated to participate almost exclusively because of the
hope of curing their illnesses. Subjectively, the patients thought they
understood the potential risks and benefits of the research, but they were
in fact unaware that the purpose of the research was to study dose
schedules and toxicity levels of drugs, not to cure them. 39
Another study examined subjects' understanding after participating in
a double-blind research study in which the major risk was receiving a
placebo. 14 Despite a comprehensive informed consent process that in-
volved a written form, verbal explanations, and even an interview by a
psychiatrist, only ten out of nineteen patients understood that the pur-
pose of the study was research. The other nine subjects thought that the
purpose of the study was "to make them better." Moreover, eighteen of
the nineteen patients reported that they decided to participate, in part,
because they expected to receive better treatment in the research ward.
41
Thus, an examination of the decision-making of terminally ill patients
136. PRESIDENT'S ADVISORY COMMITTEE, supra note 18, at 484 (noting that
"patient-subjects view research participation as a way of obtaining the best medical
care, even when participating in research holds out very little prospect of direct
benefit") (citing Paul S. Appelbaum et al., The Therapeutic Misconception: In-
formed Consent In Psychiatric Research, INT'L J. OF L. & PSYCHIATRY 5 (1982)).
See GRAY ET AL., supra note 67, at 52 (arguing that "people with HIV infection are
often desperate for a cure or an effective means of ameliorating symptoms" and
that "this desperation may lead to an increased likelihood of confusion of research
with treatment").
137. See generally C.W. LIDZ ET AL., INFORMED CONSENT: A STUDY OF
DECISION-MAKING IN PSYCHIATRY (1984).
138. See generally Christopher K. Daugherty et al., Perceptions of Cancer Pa-
tients and Their Physicians Involved in Phase I Trials, 13 J. CLIN. ONCOL. 1062-72
(1995).
139. See id.
140. See C.W. Lidz & L.H. Roth, The Signed Form: Informed Consent?, in
SOLUTIONS TO ETHICAL AND LEGAL PROBLEMS IN SOCIAL RESEARCH 145-157
(R.F. Boruch and J.S. Cecil eds., 1983) (cited in GRAY ET AL., supra note 67, at
39).
141. See id.
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undercuts the ability of the doctrine of informed consent to legitimate
research. To the extent that patient-subjects tend not to analyze the risks
of research and to presume that the doctor-researchers are always acting
in their best interests, informed consent is a fiction. For the patients who
attempt to undertake such an analysis, they may find their decision-
making capacity hamstrung by the psychological and physiological rav-
ages of their illnesses.
B. Financial and Professional Incentives
Biomedical research is no longer a pure scientific endeavor. It is an
enormous industry with billions of dollars of assets and tens or hundreds
of thousands of participants.142 As of 1988, there were over 50,000 full-
time faculty members at American medical schools.143 With their careers
dependent on obtaining research grants and publishing the results of
their work, researchers have "recruited experts in management, financial
administration, production, science writing, and marketing, along with a
host of supporting personnel, research assistants, and graduate
students."144 Researchers thus face potential conflicts of interest when-
ever the ethical requirements of research threaten to impede their per-
sonal aspirations or cut into profits of the research industry.
45
An excellent example of how much is at stake can be found in AIDS
research and the battle over the discovery of HIV. With a potential No-
bel prize at stake, and certainly the prospect of lucrative proceeds to be
derived from HIV tests and, perhaps, vaccines, French and American
researchers have been battling in court over the bragging rights for a
decade. 46 In short, there is a conflict of interest, and the greater the po-
tential payoff in terms of prestige and cash, the greater the potential for
research abuse.
147
Financial conflicts of interest are compounded by the existence of for-
142. See TIME Special Report, supra note 2, at 51.
143. See Robert U. Massey, Cultural Contents in the History of the Use of Hu-
man Subjects in Research, in THE USE OF HUMAN BEINGS IN RESEARCH 19, 22
(Stuart F. Spicker et al., eds., 1988).
144. Id.
145. See id. at 23; see also Stephenson, supra note 7, at 1827 (suggesting that
financial incentives exist to continue to conduct stem-cell transplants on breast
cancer patients - despite equivocal results - because "[a]utologous peripheral
stem-cell transplant units reportedly are moneymakers for medical centers").
146. See GRAY ET AL., supra note 67, at 1-3.
147. Seeid. at3.
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profit IRBs. Currently, only two to three percent of IRBs are commer-
cial, but the percentage is rising.'48 Furthermore, some researchers
whose experiments are rejected as scientifically unsound or unethical by
an IRB will hire a commercial IRB to review and approve the
research. 149
Professor Jay Katz, who helped develop the federal regulations, sum-
marized a number of these concerns in his 1994 testimony to
Congress. 50 First, "[t]he majority of IRB members are on the faculty of
the institutions to which the investigators belong."'' Accordingly, IRB
members are reluctant to disapprove of their colleagues' research for
fear that their own research subsequently will be subjected to similarly
harsh scrutiny. 152 Second, IRBs are under pressure from their institutions
to approve research protocols because those institutions rely on the
revenues from the research for their existence, and thus researchers are
penalized to the extent that research is slowed by efforts to comply with
ethical and regulatory obligations. 53 Third, research is increasingly sup-
148. See Vicki Brower, Vulnerable Groups at Risk from "Commercial" Ethical
Review Boards, 3 NATURE MED. 70, 70 (1997). 1
149. See id. (discussing recent testimony before the Committee on Government
Reform and Oversight's subcommittee on human resources). The author recounts
two examples of this trend. In one, a research protocol for a new drug to treat
schizophrenia was rejected by an IRB because the research would require subjects
to go untreated prior to beginning the study. The researcher, however, found a
more sympathetic IRB elsewhere to approve the study and is now defending a law-
suit after the suicide of a subject who went untreated. In the other, a physician's
protocol was rejected by one IRB because it called for asthmatic children to be
taken off their medication, but subsequently was approved by a commercial IRB
hired by the researcher to review the protocol. See id.
150. See Jay Katz, Problems in Securing Informed Consent of Subjects in Ex-
perimental Trials of Unapproved Drugs and Devises, Testimony before the U.S.
House Subcommittee on Regulation, Business Opportunities, and Technology of
the Committee on Small Business, 125-35 (May 23, 1994).
151. See id. at 131.
152. See id.
153. See id at 133. Professor Katz argues as follows:
Academic institutions rely on the revenues which accrue from the
assessment of indirect costs to the providers of grants. Research
proposals have to be generated and completed at a rapid rate to as-
sure future grant support. Thus investigators are under considerable
pressure to recruit subjects as quickly as possible to support the in-
stitutions' buildings, laboratories, staff and salaries. With respect to
the needs of their institutions, and career advancement and future
grant support as well, physician-investigators are thus the victims of
an institutional system (their own institutions and the National In-
Research on the Terminally ill
ported by pharmaceutical and biotechnology companies that use their
own private IRBs to approve the very work their investigators propose.
It should thus come as little surprise that research is rarely rejected for
ethical reasons.
54
C. Attitudes of Physician Researchers
As recently as the 1960s, physicians routinely avoided telling patients
that they had terminal illnesses, and sometimes actively misled them to
believe they did not.'5 5 Although most doctors no longer misinform their
patients, some evidence indicates that, for some patients at least, the
diagnosis of death may hasten or even cause death. 56 Thus, when doc-
tors decide not to inform their patients out of concern for their health,
doctors may be shielded from liability under the "therapeutic exception"
to the requirement of informed consent.'
57
Doctors are trained to heal, not to facilitate death and ease pain. Often
stitutes of Health) which [penalizes] them if in fulfillmentlof their
ethical disclosure obligations toward patient-subjects, the pace of
research would be slowed. These pressures impact significantly on
the speed with which' the process is conducted so that patient-
subjects will not refuse to participate.
Id.
154. See id. at 134-35.
155. See Norman B. Levy, Fatal Illness: What Should the Patient be Told?, in
PSYCHIATRIC ASPECTS, supra note 112, at 42.
In this country, the practice of informing patients about fatal ill-
nesses has changed radically since the early 1970s; before then,
there was a tendency not to tell patients their diagnoses. Fitts and
Radvin (1953) questioned 444 Philadelphia physicians concerning
their attitudes toward being forthright with their patients regarding
their fatal illness and found that on[y 37% of them usually intormed
patients of their diagnoses. In a classic study of 219 physicians at
Michael Reese hospital in Chicago (Oken (1961), only 12% stated
that their usual policy was to tell patients that they had cancer.
Feifel (1965) reported that between 10% of 31% of physicians fa-
vored letting patients know that they were dying.
Id.
156. See G.W. Milton, Self-willed Death or the Bone-pointing Syndrome, in
PSYCHOSOCIAL CARE OF THE DYING PATIENT, supra note 92, at 125-27 (arguing
that upon diagnosis of a terminal illness, some patients cause their own deaths in a
matter essentially homologous to the phenomenon where a person who has been
cursed, or "bone-pointed" by an Aboriginal witch-doctor, will often die soon after-
ward).
157. See, eg., Arato v. Avedon, 858 P.2d 598, 600 (Cal. 1993) (holding that the
jury reasonably could have found under the therapeutic exception that physician
did not have a duty to disclose life expectancy of patient with pancreatic cancer).
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it is difficult for them to assume the latter role. The wife of a terminally
ill cancer patient notes that "it is understandably difficult for doctors
who treat terminally ill patients to reconcile the need to heal ... with the
desire of some patients to let the disease take its natural course."158 One
doctor who worked with the terminally ill stated, "I've realized that for
the past 25 years when a patient of mine has been terminally ill, I'd walk
into the room talking constantly, approach the bed, and back out of the
room talking. I do this because I have nothing to offer medically and I'm
not willing to deal with the patient's emotional stress. '' 159
Doctors and staff of research facilities who work with the terminally
ill are not immune from the suffering and death that surrounds them.
Physicians fear death like anyone else, and many may be reluctant to
communicate openly with dying patients.' 60 Some studies indicate that
physicians may deny death more than the general population.16' Thus,
physicians' traditional reluctance to communicate openly with their pa-
tients may simply be a manifestation of their desire to avoid confronting
their own fears of death. 62
Regardless of the source, to the extent that old attitudes persist, physi-
cians may hesitate to communicate the details of possible courses of
treatment. As a result, the terminally ill may not receive adequate infor-
mation upon which to base informed consent decisions.
III. PROPOSED REGULATORY REFORMS
Any effective regulatory regime must balance the goal of preventing
158. Sandra L. Barger, Personal Professional Support: From a Patient's Point
of View, in PSYCHOSOCIAL CARE OF THE DYING PATIENT, supra note 92, at 67
(1978).
159. Garfield, supra note 96, at 105. Dr. Garfield notes that physicians' psy-
chological reactions mirror those of their patients; they often exhibit anger, denial,
and depression when confronted with the fact that their patients are going to soon
die. See id.
160. See Pattison, supra note 92, at 134.
161. See H. Feifel, The Function of Attitudes Towards Death, in GROUP FOR THE
ADVANCEMENT OF PSYCHIATRY, DEATH AND DYING: ATTITUDES OF PATIENT AND
DOCTOR (1965).
162. See Pattison, supra note 92, at 134-35 (1978) ("I have found that most
dying patients ... want to share their dying experience with others. It is rare that
such discussions upset the dying person. But I have seen many nurses, physicians,
and mental health personnel become nervous, anxious, upset, and distraught [at the
prospect of such discussions].").
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abuse of the terminally ill with the need to streamline the processes for
development and approval of new therapies as well as with the right of
the terminally ill to preserve their dignity and make these difficult deci-
sions themselves. This is a hard balance to strike. Regulating research to
prevent abuse slows down the process for approval of new drugs and
therapies, and may indirectly insult the dignity of patients or the integ-
rity of researchers. While accounting for these competing concerns,
certain regulatory reforms would improve the process for approving and
conducting research on the terminally ill. The proposals follow the ty-
pology of the regulations themselves. Subpart A offers structural and
institutional reforms; subpart B argues for restrictions on the types of
research in which the terminally ill may be involved; and subpart C pro-
poses and analyzes alternative ways to better ensure that the terminally
ill do not participate in research without giving their fully informed,
voluntary consent.
A. Structural and Institutional Reforms
1. Regulatory Recognition of the Vulnerability of the Terminally Ill
At a minimum, all human research regulations that discuss "vulner-
able" populations and give examples thereof should be amended to in-
clude the terminally ill. 163 Certainly some researchers, commentators,
and IRBs consider the terminally ill to be vulnerable and treat them as
such when applying the relevant regulatory provisions. 64 Yet absent
explicit recognition, the possibility remains that many researchers and
IRBs will overlook the vulnerability of their terminally ill subjects. Even
among those researchers who recognize their vulnerability, without fur-
ther impetus they may fail to take the time to understand and respond to
the unique psychological trauma induced by the diagnosis of terminal
illness. Granted, merely listing the terminally ill as a type of vulnerable
class may have little direct regulatory impact, but it will allow the regu-
lations to assume a vital hortatory role, 165 calling on researchers and
163. General regulations applicable to all vulnerable classes are discussed in
Part I.B. 1, supra.
164. Articles by a number of authors who are either researchers or members of
IRBs, or both, provide at least indirect evidence that some decision-makers treat the
terminally ill as a vulnerable class. See, e.g., KATZ, supra note 22, at 1053;
LEVINE, supra note 9, at 77-79.
165. See JOHN H. MERRYMAN ET AL., THE CIVIL LAW TRADITION: EUROPE,
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IRBs to familiarize themselves with the unique difficulties their subjects
face.
Alternatively, the regulations could explicitly define the vulnerable
populations and include the terminally ill among them. Such a step
would make the job of IRBs simpler and more mechanical: if research
involved subjects on the vulnerable list, the "vulnerability" regulations
would apply; if research did not involve such subjects, the vulnerability
regulations would not apply. The drawback of this approach, of course,
is that it would make it more difficult for the set of vulnerable popula-
tions to expand or contract according to society's notions of vulnerabil-
ity. It also would seem to strip IRBs of the discretion and responsibility
to make independent inquiries into whether subjects had an impaired
ability to make rational decisions. For subjects who were not on the
"vulnerable" list, but who nevertheless suffered some form of impair-
ment in their decision-making capacity, this could have serious conse-
quences. Moreover, from a practical standpoint, regulators have shown
persistent reluctance to attempt to define the term. Thus, the more pru-
dent approach seems to be to continue to leave the definition of "vulner-
ability" open-ended, but clarify that the term encompasses the terminally
ill.
Recognizing the vulnerability of the terminally ill would have only
minimal impact on the speed with which research is conducted, and thus
would not substantially reduce the societal benefits of such research.
The general regulations applicable to vulnerable classes are fairly unob-
trusive for researchers and IRBs alike. 166 Compliance with these provi-
sions, which vest broad discretion in the IRBs and researchers and allow
for substantial flexibility, should not affect scientific progress.
Categorizing the terminally ill as vulnerable would, however, threaten
their dignity and autonomy. Advocates for the terminally ill have been
lobbying for thirty years - culminating in the political and regulatory
success of gaining swifter access to potentially life-saving drugs 167 -
for recognition that they are not passive, vulnerable, and incapable of
understanding or coping with their diagnoses. They have demanded and
won the right to be informed. They have played an increasingly active
LATIN AMERICA, AND EAST ASIA 48-50 (1994) (discussing how within the civil law
tradition - but not the common law tradition - the law has played both hortatory
and pedagogical roles even absent coercive effect).
166. See supra Part I.B.1.
167. See supra Part I.C.
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role in steering the direction of their treatments. Considered in this light,
stigmatizing the terminally ill as "vulnerable" could be a dangerous step
backward.1
6
This concern is legitimate, but rests on the false presumption that rec-
ognizing the vulnerability of the terminally ill necessarily undermines
the project of making them more active participants in their treatment.
Vulnerability and personal autonomy are not disjunctive concepts. In-
deed, because the terminally ill are uniquely vulnerable, they deserve
greater recognition of their right to determine the course of treatment.
The psychological trauma accompanying terminal diagnosis is a crisis of
loss of self. The terminally ill patient must cognitively and emotionally
come to grips with the prospect of permanent personal annihilation. At
the same time, the patient's body may be failing, and most aspects of her
everyday life are profoundly altered. Recognition of the right of such a
patient to make both important and seemingly trivial decisions is not just
a normative proposition; it is a form of psychotherapeutic treatment. By
exercising personal autonomy, the patient regains a measure of dignity
and reaffirms the continued existence and vitality of the self.169 Active
participation in the informed consent process also may enhance patients'
ability to understand the risks and benefits of research. 70
Researchers and regulators alike have already demonstrated the ability
to understand the subtlety of this dynamic. For example, the regulations
governing research involving children recognize the possibility of the
coexistence of vulnerability and autonomy. Children are explicitly listed
as vulnerable and entitled to substantial regulatory protection.' 71 Yet, at
the same time, children are recognized as autonomous decision-makers
who generally must give their "assent" to treatment. Recognition of
168. See GRAY ET AL., supra note 67, at 37 (arguing that rigorous compliance
with informed consent provisions denies "'vulnerable populations' - including
people with AIDS - the right to make important personal choices. .. [and] [s]uch
protection is particularly questionable when its effect is to deny access to experi-
mental treatments when no effective, FDA-approved treatment is available").
169. See supra Part II.
170. See, e.g., Vijay L. Melnick et al., Clinical Research in Senile Dementia of
the Alzheimer Type, 32 J. AM. GERIATRICS Soc. 531, 536 (1984) (suggesting that
the informed consent process would be improved if potential subjects critiqued
drafts of information materials prior to their use in research), cited in NBAC
REPORT, supra note 127, at 52-53.
171. See 45 C.F.R. §§ 46.401-46.409 (1998).
172. See id. § 46.408(a). Only when the research is likely to provide a direct
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the vulnerability of the terminally ill patient will not reverse the mo-
mentum of the patients' rights movement. On the contrary, it will ad-
vance the movement by demanding researchers treat terminally ill pa-
tients not as either vulnerable or autonomous, but rather as complete
people who are grappling with the psychological impact of their ill-
nesses, but who nevertheless are entitled to make their own decisions.
2. Constitution of Institutional Review Boards
Recognition of the terminally ill as a vulnerable class would require
IRBs who work with the terminally ill to consider including an expert on
the terminally ill as a member of the IRB.173 Prior to 1988, this require-
ment was mandatory. IRBs that worked with vulnerable subjects had to
"include one or more individuals primarily concerned with the welfare
of those subjects."'174 The Interagency Committee, which proposed the
new rules, received a number of comments stating that the new, optional
rule would weaken the position of vulnerable human subjects.,75 The
Committee responded, however, by stating that it "expects that institu-
tions will use good judgment and diligence in selecting persons as IRB
members who can fulfill the requirements." 76
Assuming regulators do not adopt vulnerable population representa-
tion on IRBs as a general requirement, they nevertheless should consider
doing so for IRBs that work with the terminally ill. Such an exception
has been made for research involving prisoners, where the IRB must
include a prisoner representative. 177 Moreover, the National Bioethics
Advisory Commission (NBAC) recently recommended that "[a]ll IRBs
that regularly consider proposals involving persons with mental disor-
ders should include at least two members who are familiar with the na-
ture of these disorders and with the concerns of the population being
benefit to children that cannot be obtained except through the research may chil-
dren be included in research without their "assent." See id. "'Assent' means a
child's affirmative agreement to participate in research." Id § 46.402(b); see also
supra Part I.B.2.
173. See 45 C.F.R. § 46.107(a).
174. 45 C.F.R. § 46.107(a) (1985); see also 51 Fed. Reg. 20,204, 20,207 (1986)
(proposed June 3, 1986); 53 Fed. Reg. 45,660, 45,665 (1988) (proposed Nov. 10,
1988).
175. See 53 Fed. Reg. 45,660, 45,665 (1988).
176. See id. at 45,660, 45,665.
177. See 45 C.F.R. § 46.304; see also supra Part I.B.2.
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studied."' 8 A similar recommendation is warranted for the terminally
ill. Unlike children, for example, where issues of vulnerability are
straightforward, the vulnerability of the terminally ill is complex, highly
individuated, and subtle. Even more importantly, this vulnerability must
be balanced against the fact that the terminally ill are also competent,
autonomous adults entitled to do their own decision-making. 7 9 IRBs
should include at least one member who understands these complexities
and can adequately represent the interests of terminally ill subjects. At a
minimum, IRBs should be required to consult with an expert on the ter-
minally ill when reviewing research protocols that involve the termi-
nally ill as subjects.
This proposal has essentially no drawbacks. It would not directly af-
fect scientific progress. Indirectly, the proposal could tend to slow re-
search only to the extent that the IRBs might be inclined to scrutinize
more carefully the ethics of research involving the terminally ill. But
this is a desirable trade-off. Some might object that it is illogical to re-
quire IRB representation for the terminally ill but not for other vulner-
able classes such as the mentally ill. This may be true, but argues more
for the inclusion of IRB representatives for other vulnerable classes than
for the exclusion of representatives for the terminally ill.' 80 Requiring
representation of the terminally ill on IRBs could greatly enhance the
responsiveness of researchers to their needs, and would do so at minimal
cost to society.
3. Psychological Training for Investigators
Researchers who use the terminally ill as subjects should receive
training to ensure they understand the psychological difficulties con-
fronting their subjects. The generalized training that researchers may
have received in medical school is inadequate. Researchers, by virtue of
their frequent contact with their dying subjects, will often have a so-
phisticated intuitive understanding of the psychological difficulties their
subjects face and how they cope with them. Periodic formal training,
when coupled with this experience, should make researchers highly re-
sponsive to the psychological needs of their patients. It should also bet-
ter enable them to distinguish normal psychological responses from
178. NBAC REPORT, supra note 127, at 52-53.
179. See supra Part III.A. 1.
180. See NBAC REPORT, supra note 127, at 52-53 (recommending representa-
tion of mentally ill on IRBs).
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pathological ones, and to recognize when their subjects should be re-
ferred for psychological consultation. Ideally, psychological training for
researchers should be accompanied by formal involvement of psycholo-
gists in the research protocol.1
8'
B. Restrictions on Types of Research that May Be
Conducted Using Terminally Ill Subjects
Categorical bans on certain types of research constitute the most con-
troversial means of regulating in this arena. Whenever research is
banned, any benefit that might have been derived therefrom is lost.
Hence, regulators should not impose such restrictions lightly. Neverthe-
less, as with children and prisoners, certain types of research involving
the terminally ill warrant a presumption of coercion or undue influence
and should be outlawed even if researchers purport to obtain the in-
formed consent of their subjects.
1. Research Not Intended to Provide Direct Therapeutic Benefit to
Subjects
Generally, research should not be conducted on the terminally ill if it
is not intended to benefit them. This is true regardless of the level of risk
involved. Even if the risk of the research is seemingly minimal, IRBs
should not approve the study if it is not expected to benefit the subjects.
For example, it is inappropriate to use the terminally ill to develop
methods of arteriography1
8 2
This approach is intentionally modeled after the regulations governing
research with prisoners, 8 3 which impose an outright ban on any research
that is not related in some way to prisons or prisoners.1 4 Like prisoners,
the terminally ill are often captive and physically vulnerable. Just as
prisoners might "consent" to participate in research to try to garner favor
or to avoid retaliation, so too might the terminally ill consent to research
181. See infra Part III.C.2.
182. See generally James A. Helmsworth et al., Arteriography of the Aorta and
Its Branches by Means of the Polyethylene Catheter, 64 AM. J. ROENTGENOLOGY
196 (1950), excerpted in KATZ, supra note 22, at 1054-56. A number of patients
died as a result of the experimental methods, but the researchers argued that "it is
imperative to weigh the dangers of the procedure against the value of the informa-
tion obtained." Id. at 1056.
183. See 45 C.F.R. §§ 46.301-46.306 (1996).
184. See supra Part I.B.2.
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in which they would prefer not to be involved because they want to
please the researchers who also may be in charge of their medical
care.185 The regulations should not allow researchers to put the termi-
nally ill in the perceived conundrum of choosing between being a "good
patient" and following their true desires.
The more lenient approach applied to research involving children, and
now recommended for research involving the mentally ill,1s6 is not ap-
propriate for the terminally ill. When the risk is minimal, current regu-
lations allow children and parents to consent to research that will not
benefit the children. 8 7 In addition to children not being physically cap-
tive, like prisoners and sometimes the terminally ill, such research is
often justified because there are no other appropriate subjects available.
It is often impossible to study developmental psychology and physiol-
ogy except by employing children as research subjects. 188 This is not
true with the terminally ill. Generally, if the research is not intended to
benefit the subject of the study, other non-vulnerable subjects could be
employed.
Three narrow exceptions should be made to this ban. First, as with
research involving children, 189 when the risk involved is only slightly
over minimal risk, the terminally ill should be allowed to consent to
participate as subjects provided the research is intended to yield impor-
tant, generalized knowledge about their condition, even if it is unlikely
to benefit them personally. Second, an exception should be allowed if
HHS consults with appropriate legal, medical, and ethical experts and
concludes that the research is ethical; presents an important opportunity
to learn about the subjects' condition; and ensures that subjects will
participate only after giving their informed consent. 190 Third, sociologi-
cal, psychological and epidemiological research that presents no medical
risk to subjects should not be banned. Particularly with AIDS and other
infectious disease research, these types of studies are of vital impor-
185. See supra Part II.A.4.
186. See NBAC REPORT, supra note 127, at 60-61.
187. See 45 C.F.R. § 46.404; see supra Part I.B.2.
188. See NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF
BIOMEDICAL AND BEHAVIORAL RESEARCH, RESEARCH INVOLVING CHILDREN 21-
23 (1977).
189. See 45 C.F.R. § 46.406 (1998).
190. This proposal is again modeled after an analogous rule currently applied to
research involving children as subjects. See id. § 46.407.
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tance. 191
These proposed restrictions on research strike a balance between pro-
tecting the terminally ill and ensuring that scientific progress with re-
gard to terminal illnesses is not slowed. There is, however, a downside.
First, this proposal would reduce the pool of potential research subjects
for unrelated research. The terminally ill, who are often hospitalized, are
ideal research subjects: their vital signs are constantly monitored, their
diet can be easily tracked, and they are unlikely to move away.192 Pro-
hibiting certain types of research also reduces patient autonomy and
choice. In many cases, this proposal would prevent the terminally ill
patient from volunteering to be a research subject out of genuine altru-
ism. For some, this concern is undoubtedly real, but the vast majority of
terminally ill patients participate in research because they hope to cure
or ameliorate their own conditions.
93
Recognizing these potential drawbacks, this proposal is nevertheless
justified. Informed consent requirements are insufficient to protect the
interests of the terminally ill. Without such a ban on unrestricted use of
the terminally ill as research subjects, they remain highly vulnerable to
abuse.
2. Research Intended to Provide a Direct Therapeutic Benefit to
Subjects
There should be few additional restrictions 194 on the types of research
that will be approved when the research is intended to benefit terminally
ill subjects. There are, however, two requirements imposed in the regu-
191. See GRAY ET AL., supra note 67, at 35 (noting, however, that ensuring the
informed consent of subjects is of heightened importance in AIDS studies that do
not provide a direct benefit to patients because subjects may be unaware that the
studies are not intended for their benefit).
192. See JOHN AIKIN, THOUGHTS ON HOSPITALS 79 (1971) cited in William
Bynum, Reflections on the History of Human Experimentation, in THE USE OF
HUMAN BEINGS IN RESEARCH, supra note 143, at 36 (1988). Note that similar
arguments have been made for using prisoners as research subjects. These argu-
ments are resurfacing now as prisoners who suffer from illnesses such as AIDS
lobby for the right to be included in drug studies. See generally PETER B. MEYER,
DRUG EXPERIMENTS ON PRISONERS (1976); see also supra Part I.C.
193. See Daugherty et al., supra note 6, at 896.
194. There are a number of general restrictions on the types of research that may
be done designed to ensure that the research is good science. See 45 C.F.R. §
46.111 (1998); see also supra Part I.A.2.
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lations governing research on children that should also be applied to
research involving the terminally ill.
First, the general regulations applicable to all research require IRBs to
determine that the "risks to subjects are reasonable in relation to antici-
pated benefits, if any, to subjects, and the importance of the knowledge
that may reasonably be expected to result."'195 When research uses and
intends to benefit child subjects, however, the IRB must find that "the
risk is justified by the anticipated benefit to the subjects."'196 General
knowledge is not weighed in the risk/benefit calculus. The same limita-
tion should be imposed when experimentation involves the terminally
ill. If the risks to the terminally ill subjects outweigh the potential bene-
fits to them, the subjects should not be allowed to "consent" in the name
of science.
Second, the research should not be approved if a treatment with a
more favorable risk/benefit ratio is available to treat the patients' condi-
tions. Again, this mirrors the requirement applicable to research involv-
ing children.' 97 Researchers' primary obligation when working with the
terminally ill should be to treat them as patients, and if better therapies
are available, they should be employed.
The primary objection to these restrictions is that they could poten-
tially stifle important medical developments. An IRB could conceivably
not approve the research that otherwise would lead to the general cure
for cancer on the grounds that the study is so risky, and the possibility of
benefit so remote, that there are better, alternative treatments available.
For this reason, an exception should be created to allow research to go
forward if HHS determines after consultation that the research presents
an opportunity for an important advance in the understanding of the ter-
minal condition.
195. 45 C.F.R. § 46.11 1(a)(2).
196. Id. § 46.405(a).
197. See id. § 46.405(b) ("[T]he relation of the anticipated benefit to the risk
[must be] at least as favorable to the subjects as that presented by available alterna-
tive approaches.").
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C. Further Safeguards to Ensure the Informed
Consent of Subjects
1. Subject Advocates
Used in conjunction with other regulatory reforms suggested above, 9
subject advocates could greatly enhance the informed consent process in
human research. 199 Current regulations suggest that when research in-
volves pregnant women, fetuses, or human in vitro fertilization, it may
be appropriate to employ subject advocates to ensure the adequacy of
the informed consent process. 200 Nowhere else in the regulations, how-
ever, are subject advocates mentioned. 20 1 Thus, regulators could have
considered and rejected the notion of requiring the use of subject advo-
cates. Indeed, a number of participants in the regulatory debate in 1982
lobbied for the use of subject advocates, but many modern commenta-
tors have rejected the idea as overly intrusive. 2 Nevertheless, requiring
the use of subject advocates for research involving the terminally ill is
justified.
As argued in Part II, a number of factors taken together make the ter-
minally ill uniquely vulnerable to coercion and undue influence in the
informed consent process. Many of these factors could be neutralized, or
at least mitigated, through the use of a subject advocate.0 3 A subject
advocate trained to recognize the psychological symptoms that accom-
pany terminal diagnoses could help patients cope with depression and
198. See supra Parts III.A & III.B.
199. NBAC has suggested the use of "independent advisors" for research in-
volving the mentally ill that entails more than minimal risk. See NBAC REPORT,
supra note 127, at 37.
200. See 45 C.F.R. § 46.205(a)(2) (1998); see also supra Part I.B.2.
201. See 45 C.F.R. §§ 46.101-46.409.
202. Richard J. Bonnie, Research With Cognitively Impaired Subjects, 54 ARCH.
GEN. PSYCHIATRY 105, 111 (1997) (citing R. Dresser, Mentally Disabled Research
Subjects: The Enduring Policy Issues, 276 JAMA 67 (1996); J.W. Berg, Legal and
Ethical Complexities of Consent with Cognitively Impaired Research Subjects:
Proposed Guidelines, 24 J. LAW. MED. ETHICS 18 (1996)).
203. See generally M.D. Dowdy et al., A Study of Proactive Ethics Consultation
for Critically and Terminally Ill Patients with Extended Lengths of Stay, 26 CRIT.
CARE MED. 252 (1998) (finding that proactive ethics consultation for the terminally
ill increased the quality and quantity of doctor-patient communication, led to more
decisions to forgo life-sustaining treatment, and reduced the average length of stay
in the intensive care unit).
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anxiety that they may feel, 20 4 making them better able to analyze the
information they receive. Subject advocates also could ask the difficult
questions of researchers which the subjects themselves may be reluctant
to ask due to their dependence on and desire to please the researchers,205
thus ensuring that the information subjects receive is more complete.
Finally, researchers who for personal, professional, or financial reasons
otherwise might be reluctant to disclose all of the relevant
information, 206 would be more inclined to make full disclosure knowing
that the informed consent process will be carefully scrutinized on the
subjects' behalf. Subject advocates should have adequate education and
training in the psychology of terminal illness, 2 7 as well as sufficient
medical knowledge to fully understand the risks and benefits of the re-
search. In addition, to preserve their independence, subject advocates
should not be employees of the institution conducting the research.
There are, of course, potential drawbacks. The use of subject advo-
cates could drive a wedge between the subject and researcher, alienating
the subject and angering the researcher. It could, incrementally, slow the
progress of science. And most importantly, it could be viewed by sub-
jects as personally invasive. Accordingly, the role of the subject advo-
cate should be carefully circumscribed by a number of limitations.
First, subject advocates should not be required unless the experiment
presents more than minimal risk to subjects. For low-risk experiments,
where the stakes are not as high, IRBs should be left with discretion to
decide whether to employ subject advocates. Second, research subjects
should be able to decline to use a subject advocate. Whether to partici-
pate in research is an extremely intimate and personal decision, often
made more on an emotional than on a cognitive level. Especially with
subjects already experiencing a crisis of identity resulting from their
illnesses, 208 their preferences should be respected. Third, to minimize
costs2°9 and delay, subject advocates should be used only to the extent
204. See supra Parts II.A. 1 & II.A.2.
205. See supra Part II.A.4.
206. See supra Parts II.B & II.C.
207. In appropriate cases, the roles of psychologist, see infra Part III.C.2, and
subject advocate could be combined, thus allowing a trusting relationship to form
between the subject and the psychologist/advocate.
208. See supra Part II.A.
209. The costs of subject advocates presumably would be borne, like other costs
of the research, by the research sponsor, the subjects themselves, or by a third party
payer, depending on the research. It is important to minimize costs because, at the
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necessary to ensure the adequacy of informed consent, or as otherwise
requested by the subject. Thus for many subjects, an initial meeting with
the subject advocate and the inclusion of the subject advocate in the in-
formed consent negotiations with the researcher may be sufficient.
With these caveats taken into account, requiring subject advocates for
any research involving more than minimal risk should have little impact
on scientific progress, the dignity of the subjects, or the sanctity of the
relationship between subject and researcher.
2. Psychological Evaluation and Care
Given the normal psychological response to terminal illness as well as
the prevalence of psychological disorders among the terminally ill,
210
psychologists should examine subjects to determine if they: (1).are ex-
periencing normal psychological response to the terminal illness; (2) are
suffering from a psychological disorder but are legally competent; or (3)
are legally incompetent. 21' Like subject advocates, 212 the psychologist
should be independently employed to preserve neutrality. This initial
screening would then affect how informed consent is obtained.
On either end of the psychological spectrum, there is little, if any,
controversy. Legally incompetent persons cannot consent to be research
subjects without the use of a surrogate decision-maker.21 3 The precise
procedures for obtaining proxy consent by a surrogate are complex,
evolving, and vary from state to state. 214 Generally, however, a family
member or court-appointed guardian will be able to consent on behalf of
margin, cost escalation could squeeze out some deserving subjects or prevent im-
portant research from being conducted.
210. See supra Part II.A.2.
211. For a similar argument, see Bonnie, supra note 202, at 111 (arguing that
whenever there is a possibility of decision-making incapacity, "IRBs should require
investigators to use a structured protocol for assessing decision-making capacity
and identifying subjects with a possible impairment"). But see Pelligrino, supra
note 134, at 1521 (noting that palliative care patients must give their informed con-
sent to the psychosocial aspects of their care as well as to medical treatments).
212. See supra Part III.C.1.
213. See 45 C.F.R. § 116 (1997); see also GRAY ET AL., supra note 67, at 36
(arguing that "[p]eople with debilitating illnesses, such as AIDS (especially when
patients are demented or hospitalized), would never profit from research if inde-
pendent competent consent was always required").
214. See Bonnie, supra note 202, at 110.
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an incompetent person to participate in research intended for her
benefit." 5
Conversely, persons who are merely suffering from the normal psy-
chological effects of terminal illness diagnosis should be allowed to
consent on their own behalf. To require more would be overly paternal-
istic and an insult to autonomy. Steps should nevertheless be taken to
ensure the integrity of the informed consent process. Unless medically
necessary, the informed consent process should not take place during the
acute anxiety phase that accompanies diagnosis with terminal illness,
216
and subject advocates should be made available to assist them.
21 7
Persons who have a psychological disorder of some sort, but who are
legally competent, present the most difficulty. On the one hand, the
presence of a psychological disorder inherently compromises the legiti-
macy of informed consent. Thus, some might argue that terminally ill
persons suffering from such disorders should simply be excluded from
research. On the other hand, if a patient insists on participating in the
research and is legally competent to consent, should researchers or
regulators have the right to tell him otherwise? This question is difficult
precisely because it pits the norm of informed consent against the norm
of personal autonomy. Closer scrutiny, however, suggests that personal
autonomy should prevail, and that terminally ill persons suffering from
psychological disorders should be allowed to consent to participate in
research.
The doctrine of informed consent has taken on direct normative con-
notations in the modern regulatory state. Researchers must obtain in-
formed consent, in part, because they ought to obtain informed consent.
In reality, however, the normative content of the informed consent doc-
trine is derivative, grounded in a more basic ethical vision of the
autonomous individual. The Nuremberg Code states that "[the research
subject] should be so situated as to be able to exercise free power or
choice, without the intervention of any element of force, fraud, deceit,
duress, overreaching, or other ulterior form of constraint or coercion. 218
In short, the doctrine of informed consent is designed to promote the
215. See id.
216. See supra Part II.A.1.
217. See supra Part III.C.1.
218. TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY
TRIBUNALS UNDER CONTROL COUNCIL LAW NO. 10 181-82 (1949).
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ethic of respect for persons. 21 9 It would be ironic indeed if in the name
of respect for the terminally ill person suffering from a psychological
disorder regulators were to refuse to allow her to participate in an ex-
periment that has already been found by an IRB to represent a reason-
able risk.220 However serious the concerns about informed consent may
be, these concerns cannot justify the affront to personal autonomy such a
refusal would entail.
This conclusion also reflects practical concern over the application of
a rule that would exclude the terminally ill with psychological disorders
from research. In essence, whether a person was allowed to participate
in research - some of which would be potentially life-saving - would
turn on the subtle distinctions that psychologists would have to draw to
distinguish "normal" psychological responses to terminal illness from
psychopathological ones. This would vest enormous power in the hands
'of psychologists and put inordinate faith in their ability to draw the
sometimes extremely fine lines between normal and abnormal. .
One commentator has argued for an intermediate approach that in
theory represents a good compromise, but in practice presents difficul-
ties. Richard Bonnie suggests that when persons have impaired decision-
making capacity but are legally competent, the regulations should re-
quire only their assent,221 which perhaps could be accompanied by the
use of a surrogate decision-maker.222 This procedure, however, could
have unintended consequences.
If different informed consent procedures were used for classes of per-
sons with partially impaired decision-making capacity, the sponsors of
the research might assume that there was something psychologically
"wrong" with those subjects. As a result, such people could end up be-
ing excluded from research altogether. With profits hanging entirely on
the success of research, sponsors seek out subjects who have the afflic-
tion that their drug or therapy is designed to treat, but who otherwise are
219. See LEVINE, supra note 9, at 96 (citing K. Lebacqz & R.J. Levine, Respect
for Persons and Informed Consent to Participate in Research, 25 CLIN. RES. 101
(1977); K. Lebacqz & R.J. Levine, Informed Consent in Human Research: Ethical
and Legal Aspects, in W.T. REICH, ENCYCLOPEDIA OF BIOETHICS 754 (1978)).
220. 45 C.F.R. § 46.111. This Article suggests that only benefits to the termi-
nally ill research subject, not benefits to scientific advancement, should be consid-
ered in the risk/benefit calculus. See supra Part III.B.2.
221. This term and its technical definition are borrowed from the regulations
governing research on children. See 45 C.F.R. §§ 46.402(b), 46.408.
222. See Bonnie, supra note 202, at 110.
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as healthy as possible.223 Given the increased prevalence of suicide and
the decreased general resiliency of persons with some psychological
disorders, 224 research sponsors will seek to eliminate these persons from
their studies so as to avoid contamination of research results. 225 Thus,
even if the regulations allowed for their participation through assent and
proxy consent, such subjects could be effectively excluded for fear of
research "contamination."
In sum, all potential research subjects suffering from terminal ill-
nesses should receive psychological evaluations. Those who are legally
incompetent may participate through proxy consent. Those who are le-
gally competent should be able to consent on their own, regardless of
whether they suffer from a psychological disorder or are experiencing a
normal response to their illnesses. In addition, ongoing psychological
care and monitoring should be available to subjects during the research,
but patients should be able to decline psychological care at their discre-
tion. Finally, all psychological evaluations and consultations should be
strictly confidential so as to prevent research sponsors from excluding
potential subjects to ensure favorable research results.
CONCLUSION
Federal regulations governing human research provide special protec-
tions to "vulnerable" populations such as children and prisoners who
may be incapable of giving their voluntary informed consent to partici-
pate as research subjects. No such protections are extended to the termi-
nally ill. Indeed, over the past fifteen years AIDS activists have fought
for deregulation, and the terminally ill now have earlier access to ex-
perimental drugs when there are no adequate therapies available, and
promising new drugs for the terminally ill are put on a fast track for
regulatory approval. The terminally ill have come to be seen by re-
searchers and regulators alike not as passive and weak, but as autono-
mous agents with the right to evaluate information and make their own
223. Interview with David Nettleton, Software Validation Specialist, Cell
Therapeutics, Inc., Seattle, Wash. (Apr. 4, 1998) [hereinafter Nettleton Interview].
224. See generally Pola Grzybowska & Ilora Finlay, The Incidence of Suicide in
Palliative Care Patients, 11 PALLIATIVE MED. 313 (1997).
225. Nettleton Interview, supra note 223. Cell Therapeutics is a small Seattle
biotechnology company whose stock dropped from $15 to $3 per 'share after poor
results were obtained during a Phase I drug study that may have been contami-
nated. See id.
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decisions. These important gains, however, have tended to obfuscate the
fact that the terminally ill are highly vulnerable to coercion and undue
influence by inattentive or unethical researchers.
A confluence of factors works together to make the terminally ill vul-
nerable to research abuse. The terminally ill are desperate for a cure and
often suffer from depression, anxiety, or other psychological disorders
that may be exacerbated by the physiological symptoms of their ill-
nesses. These psychological symptoms make rational decision-making
extremely difficult. Also, the terminally ill are often hospitalized, feel
dependent on the researchers in whose hands they have placed their
lives, and as a result may be reluctant to ask difficult questions -
wanting instead to play the good patient to curry favor and to avoid re-
prisals. Often, patients simply presume that whatever their doctor rec-
ommends is in their best interest, and fail to understand the dual roles of
the physician/researcher. Moreover, researchers are under tremendous
financial and professional pressures to complete their studies quickly
and publish the results, and thus may be reluctant to say or do things that
will decrease the likelihood of enrolling eligible subjects.
Accordingly, regulatory reforms need to be made to better protect the
terminally ill and ensure that they participate as subjects in research
only after giving their truly informed consent. The regulations should
recognize the terminally ill as vulnerable, require a representative of the
terminally ill to be a member on IRBs that work with the terminally ill,
and require psychological training for researchers who work with the
terminally ill. Also, research generally should be conducted on the ter-
minally ill only if it is intended to benefit them. Finally, psychological
evaluations and subject advocates should be employed to protect the
integrity of the informed consent process.
Inevitably, regulation of human research involves tradeoffs between
the personal autonomy and rights of research subjects, potential benefits
to society, and the need to prevent research abuse. Reasonable people
will differ as to how this balance should be struck. Nevertheless, it is
critical that researchers, regulators, and the terminally ill engage with
these issues. This Article is intended to provide a framework and start-
ing point for that debate.
